Magnetic resonance spectroscopy to measure hepatic to hepatic steatosis in the general population

American Journal of Physiology - Endocrinology and Metabolis 288, E462-E468

DOI: 10.1152/ajpendo.00064.2004

Citation Report

#	Article	IF	CITATIONS
1	Methodological approaches to the study of metabolism across individual tissues in man. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 501-510.	1.3	9
2	Relationship between body composition changes and changes in physical function and metabolic risk factors in aging. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 523-528.	1.3	135
3	Nonalcoholic fatty liver disease in the pediatric population: a review. Current Opinion in Pediatrics, 2005, 17, 636-641.	1.0	109
4	Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide. Liver International, 2005, 25, 490-500.	1.9	43
5	Recent concepts in non-alcoholic fatty liver disease. Diabetic Medicine, 2005, 22, 1129-1133.	1.2	262
6	Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E935-E939.	1.8	139
7	Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care, 2005, 28, 1518-1523.	4.3	41
8	Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. Metabolic Syndrome and Related Disorders, 2005, 3, 316-327.	0.5	3
9	Invasive and non-invasive investigations for non-alcoholic steatohepatitis: The benefit of histology. Scandinavian Journal of Gastroenterology, 2005, 40, 1260-1260.	0.6	6
10	Alanine Aminotransferase Levels and Fatty Liver in Childhood Obesity: Associations with Insulin Resistance, Adiponectin, and Visceral Fat. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4287-4294.	1.8	330
11	Opposed-Phase MRI for Fat Quantification in Fat-Water Phantoms with 1H MR Spectroscopy to Resolve Ambiguity of Fat or Water Dominance. American Journal of Roentgenology, 2006, 187, W103-W106.	1.0	37
12	A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol. American Journal of Human Genetics, 2006, 78, 410-422.	2.6	495
14	Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. Digestive and Liver Disease, 2006, 38, 789-801.	0.4	28
15	Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): The other face of the coin of histology. Medical Hypotheses, 2006, 66, 679-680.	0.8	0
16	Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology, 2006, 45, 600-606.	1.8	499
17	Multiple voxel 1H MR spectroscopy of phosphorylase-b kinase deficient patients (GSD IXa) showing an accumulation of fat in the liver that resolves with aging. Journal of Hepatology, 2006, 45, 851-855.	1.8	14
18	Protocol for measurement of liver fat by computed tomography. Journal of Applied Physiology, 2006, 100, 864-868.	1.2	69
19	Childhood tufted angioma. Pathology, 2006, 38, 268-270.	0.3	5

#	Article	lF	CITATIONS
20	Invasive and non-invasive investigations for tamoxifen-induced non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy. Pathology, 2006, 38, 270-271.	0.3	2
21	Chapter 13 Hepatic CCAAT/enhancer binding protein β (C/EBPβ): engineer of diabetes, obesity, and inflammatory disease processes. Advances in Molecular and Cellular Endocrinology, 2006, 5, 255-319.	0.1	0
22	Streptococcus bovis Bacteremia Associated With Acute Cholecystitis. Journal of Clinical Gastroenterology, 2006, 40, 454-456.	1.1	5
23	Invasive and Noninvasive Investigations for Pediatric Nonalcoholic Liver Fatty Disease: Time to Move Beyond Liver Biopsy. Journal of Clinical Gastroenterology, 2006, 40, 456.	1.1	0
24	Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 413-427.	0.9	214
26	Computed Tomography Features of Nonalcoholic Steatohepatitis With Histopathologic Correlation. Journal of Computer Assisted Tomography, 2006, 30, 37-43.	0.5	80
27	Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver. Experimental Biology and Medicine, 2006, 231, 1287-1299.	1.1	155
28	Adiposity of the Heart*, Revisited. Annals of Internal Medicine, 2006, 144, 517.	2.0	337
29	Change in Liver Size and Fat Content after Treatment with Optifast [®] Very Low Calorie Diet. Obesity Surgery, 2006, 16, 697-701.	1.1	201
30	Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology, 2006, 43, S99-S112.	3.6	2,116
32	Serum Resistin and Hepatic Fat Content in Nondiabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5122-5125.	1.8	43
33	Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E697-E703.	1.8	105
34	Fatty Liver: Imaging Patterns and Pitfalls. Radiographics, 2006, 26, 1637-1653.	1.4	362
35	Saturated Fatty Acids Promote Endoplasmic Reticulum Stress and Liver Injury in Rats with Hepatic Steatosis. Endocrinology, 2006, 147, 943-951.	1.4	453
36	Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS. Journal of Lipid Research, 2006, 47, 310-317.	2.0	27
37	No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB Journal, 2006, 20, 2180-2180.	0.2	18
38	Liverâ€directed overexpression of mitochondrial glycerolâ€3â€phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB Journal, 2006, 20, 434-443.	0.2	108
39	Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): The need for biochemical markers. Scandinavian Journal of Gastroenterology, 2006, 41, 372-372.	0.6	4

#	Article	IF	CITATIONS
40	Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18273-18277.	3.3	354
41	Pancreatic Fat Content and β-Cell Function in Men With and Without Type 2 Diabetes. Diabetes Care, 2007, 30, 2916-2921.	4.3	331
42	Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E829-E835.	1.8	120
43	Hypertension and fatty liver: guilty by association?. Journal of Human Hypertension, 2007, 21, 264-270.	1.0	45
44	Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. Endocrine Research, 2007, 32, 59-69.	0.6	18
45	Magnetic Resonance Spectroscopy of Hepatic Lipid Content and Associated Risk Factors in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 312-317.	0.9	54
46	Age-Related Changes in Intramyocellular Lipid in Humans by in vivo ¹ H-MR Spectroscopy. Gerontology, 2007, 53, 218-223.	1.4	60
47	Cardiac Steatosis in Diabetes Mellitus. Circulation, 2007, 116, 1170-1175.	1.6	535
48	Intrahepatic Fat Accumulation and Alterations in Lipoprotein Composition in Obese Adolescents. Diabetes Care, 2007, 30, 3093-3098.	4.3	123
49	Myocardial Lipid Accumulation in the Diabetic Heart. Circulation, 2007, 116, 1110-1112.	1.6	26
50	Habitual Physical Activity Is Associated With Intrahepatic Fat Content in Humans. Diabetes Care, 2007, 30, 683-688.	4.3	273
51	Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 458-469.	2.9	78
52	Effect of liver fat on insulin clearance. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1709-E1715.	1.8	174
54	Fatty liver and the metabolic syndrome. Current Opinion in Gastroenterology, 2007, 23, 193-198.	1.0	95
55	Relationship Among Histologic, Radiologic, and Biochemical Assessments of Hepatic Steatosis. Journal of Clinical Gastroenterology, 2007, 41, 206-210.	1.1	50
56	Effect of Pioglitazone Therapy on Myocardial and Hepatic Steatosis in Insulin-Treated Patients with Type 2 Diabetes. Journal of Investigative Medicine, 2007, 55, 230-236.	0.7	63
57	Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver. Cell Metabolism, 2007, 6, 69-78.	7.2	448
58	Role of Radiologic Modalities in the Management of Non-alcoholic Steatohepatitis. Clinics in Liver Disease, 2007, 11, 37-54.	1.0	180

#	Article	IF	CITATIONS
59	Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men. Applied Physiology, Nutrition and Metabolism, 2007, 32, 265-272.	0.9	38
60	Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. Medical Clinics of North America, 2007, 91, 1125-1149.	1.1	136
61	Associations between abdominal adiposity, exercise, morbidity, and mortality. Applied Physiology, Nutrition and Metabolism, 2007, 32, 1210-1211.	0.9	3
62	Liver Fat in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3490-3497.	1.8	386
63	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. L Endocrinologo, 2007, 8, 136-143.	0.0	0
65	Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Translational Research, 2007, 149, 114-125.	2.2	41
66	Rapid significant weight loss and regional lipid deposition: Implications for insulin sensitivity. Obesity Research and Clinical Practice, 2007, 1, 7-16.	0.8	13
67	Interethnic Differences in Muscle, Liver and Abdominal Fat Partitioning in Obese Adolescents. PLoS ONE, 2007, 2, e569.	1.1	124
68	Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology, 2008, 47, 51-58.	3.6	182
69	Assessment of Intrahepatic Triglyceride Content Using Magnetic Resonance Spectroscopy. Journal of the Cardiometabolic Syndrome, 2007, 2, 136-138.	1.7	42
70	Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2007, 21, 137-142.	1.2	42
71	Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity. Diabetes, 2007, 56, 1960-1968.	0.3	279
72	Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia, 2007, 50, 404-413.	2.9	169
73	Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia, 2007, 50, 2356-2365.	2.9	164
74	Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia, 2008, 51, 648-656.	2.9	87
75	Routine Liver Biopsy to Screen for Nonalcoholic Fatty Liver Disease (NAFLD) during Cholecystectomy for Gallstone Disease: Is it Justified?. Journal of Gastrointestinal Surgery, 2008, 12, 2097-2102.	0.9	27
76	Hypertension and hepatic steatosis. Current Hypertension Reports, 2008, 10, 182-187.	1.5	3
77	Comparative MR study of hepatic fat quantification using singleâ€voxel proton spectroscopy, twoâ€point dixon and threeâ€point IDEAL. Magnetic Resonance in Medicine, 2008, 59, 521-527.	1.9	188

#	Article	IF	CITATIONS
78	First, do no harm: The question of liver biopsy in living liver donors. Liver Transplantation, 2008, 14, 420-422.	1.3	4
79	Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology, 2008, 47, 1513-1523.	3.6	145
80	The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry, 2008, 19, 567-576.	1.9	203
81	Insulin Sensitivity Is Correlated with Subcutaneous but Not Visceral Body Fat in Overweight and Obese Prepubertal Children. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2122-2128.	1.8	76
82	Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. European Radiology, 2008, 18, 806-813.	2.3	40
83	Effect of 6â€Month Calorie Restriction and Exercise on Serum and Liver Lipids and Markers of Liver Function. Obesity, 2008, 16, 1355-1362.	1.5	178
84	Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2008, 40, 1461-1465.	9.4	2,764
85	Assessment of <i>in vivo</i> 1H magnetic resonance spectroscopy in the liver: a review. Liver International, 2008, 28, 297-307.	1.9	61
86	Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using ¹ H and ³¹ P magnetic resonance spectroscopy. Liver International, 2008, 28, 675-681.	1.9	12
87	Visceral adipose tissue area is an independent risk factor for hepatic steatosis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 900-907.	1.4	130
88	Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery. Diabetes, Obesity and Metabolism, 2008, 10, 661-667.	2.2	32
89	Review article: epidemiology, pathogenesis and potential treatments of paediatric nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 13-24.	1.9	124
90	Hepatic fat content is a determinant of postprandial triglyceride levels in type 2 diabetes mellitus patients with normal fasting triglyceride. Metabolism: Clinical and Experimental, 2008, 57, 644-649.	1.5	5
91	Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2008, 134, 424-431.	0.6	484
92	Liver, Muscle, and Adipose Tissue Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects. Gastroenterology, 2008, 134, 1369-1375.	0.6	509
93	Increased Liver Fat, Impaired Insulin Clearance, and Hepatic and Adipose Tissue Insulin Resistance in Type 2 Diabetes. Gastroenterology, 2008, 135, 122-130.	0.6	294
94	Liver stiffness values in healthy subjects: Implications for clinical practice. Journal of Hepatology, 2008, 48, 529-531.	1.8	13
95	Lipid accumulation in non-adipose tissue and lipotoxicity. Physiology and Behavior, 2008, 94, 231-241.	1.0	408

\mathbf{c}	TAT	ION		DO	DT
ι.	IAI	ION	KF.	РΟ	ואו

#	Article	IF	CITATIONS
96	Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. European Journal of Radiology, 2008, 66, 313-320.	1.2	39
97	1H MR spectroscopy of skeletal muscle, liver and bone marrow. European Journal of Radiology, 2008, 67, 275-284.	1.2	97
98	Non-invasive diagnosis of steatosis and fibrosis. Diabetes and Metabolism, 2008, 34, 674-679.	1.4	56
99	Fatty Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 27-38.	1.1	717
100	Liver Fat Content and T2*: Simultaneous Measurement by Using Breath-hold Multiecho MR Imaging at 3.0 T—Feasibility. Radiology, 2008, 247, 550-557.	3.6	114
101	Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2008, 2, 217-231.	1.4	15
102	Identification and Characterization of Metabolically Benign Obesity in Humans. Archives of Internal Medicine, 2008, 168, 1609.	4.3	869
103	Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovascular Research, 2008, 79, 269-278.	1.8	121
104	The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. European Heart Journal, 2008, 29, 1516-1522.	1.0	114
105	Liver Fat Is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects. Diabetes Care, 2008, 31, 165-169.	4.3	200
106	Fatty Liver Is Independently Associated With Alterations in Circulating HDL2 and HDL3 Subfractions. Diabetes Care, 2008, 31, 366-368.	4.3	55
107	Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut, 2008, 57, 649-654.	6.1	164
108	Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews, 2008, 29, 939-960.	8.9	455
109	Effects of Short-Term High-Fat, High-Energy Diet on Hepatic and Myocardial Triglyceride Content in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2702-2708.	1.8	99
110	Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 118-124.	1.8	51
111	Insulin-Like Growth Factor Binding Protein 1 as a Novel Specific Marker of Hepatic Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4867-4872.	1.8	64
112	The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective. Seminars in Liver Disease, 2008, 28, 339-350.	1.8	624
113	Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Review of Gastroenterology and Hepatology, 2008, 2, 59-79.	1.4	12

	Сіта	tion Report	
#	Article	IF	Citations
114	Exercise and the fatty liver. Applied Physiology, Nutrition and Metabolism, 2008, 33, 802-807.	0.9	17
115	Association between dietary fat intake, liver fat, and insulin sensitivity in sedentary, abdominally obese, older men. Applied Physiology, Nutrition and Metabolism, 2008, 33, 239-245.	0.9	9
116	Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans. Journal of Investigative Medicine, 2008, 56, 780-785.	0.7	50
117	Fasting in healthy subjects is associated with intrahepatic accumulation of lipids as assessed by 1H-magnetic resonance spectroscopy. Clinical Science, 2008, 114, 547-552.	1.8	55
118	Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis. Current Enzyme Inhibition, 2008, 4, 100-108.	0.3	1
119	The Effect of a Probiotic on Hepatic Steatosis. Journal of Clinical Gastroenterology, 2008, 42, 1117-1119	Э. 1.1	49
120	Nephrolithiasis as a systemic disorder. Current Opinion in Nephrology and Hypertension, 2008, 17, 304-309.	1.0	132
121	Diet and nonalcoholic fatty liver disease. Current Opinion in Lipidology, 2008, 19, 25-29.	1.2	23
122	Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. American Journal of Clinical Nutrition, 2008, 88, 257-262.	2.2	97
123	Hepatitis C Virus-Infected Patients Are â€~Spared' from the Metabolic Syndrome but Not from Insuli Resistance. A Comparative Study of Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-Related Steatosis. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 273-278.	n 1.8	27
124	Measurement of Hepatic Lipid: High-Speed T2-Corrected Multiecho Acquisition at ¹ H MR Spectroscopy—A Rapid and Accurate Technique. Radiology, 2009, 252, 568-576.	3.6	142
125	Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene. Diabetes, 2009, 58, 2616-2623.	0.3	291
126	Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proceedings of the United States of America, 2009, 106, 15430-15435.	3.3	853
127	Role of ectopic fat in the pathogenesis of insulin resistance. Clinical Lipidology, 2009, 4, 457-464.	0.4	5
128	Use of 3.0-T MR Imaging for Evaluation of the Abdomen. Radiographics, 2009, 29, 1547-1563.	1.4	50
129	Noninvasive Quantification of Pancreatic Fat in Humans. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4070-4076.	1.8	167
130	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Circulation, 2009, 119, 1711-1719.	1.6	117
131	Quantification of Liver Fat Content: Comparison of Triple-Echo Chemical Shift Gradient-Echo Imaging and in Vivo Proton MR Spectroscopy. Radiology, 2009, 250, 95-102.	3.6	170

#	Article	IF	CITATIONS
132	Imaging Biochemistry Noninvasively: Magnetic Resonance Spectroscopy in Liver Disease. Journal of Parenteral and Enteral Nutrition, 2009, 33, 726-728.	1.3	0
133	Imaging-based Quantification of Hepatic Fat: Methods and Clinical Applications. Radiographics, 2009, 29, 1253-1277.	1.4	276
134	High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut, 2009, 58, 1281-1288.	6.1	238
135	Nonalcoholic Fatty Liver Disease: Rapid Evaluation of Liver Fat Content with In-Phase and Out-of-Phase MR Imaging. Radiology, 2009, 250, 130-136.	3.6	110
136	Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with 1H magnetic resonance spectroscopy. Metabolism: Clinical and Experimental, 2009, 58, 1724-1730.	1.5	89
139	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009, 49, 306-317.	3.6	491
140	Ethnic differences in hepatic steatosis: An insulin resistance paradox?. Hepatology, 2009, 49, 791-801.	3.6	309
141	Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology, 2009, 50, 85-93.	3.6	82
142	Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 2009, 50, 1105-1112.	3.6	515
143	Quantitative analysis of T2â€correction in singleâ€voxel magnetic resonance spectroscopy of hepatic lipid fraction. Journal of Magnetic Resonance Imaging, 2009, 29, 629-635.	1.9	64
144	Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. Journal of Magnetic Resonance Imaging, 2009, 30, 145-152.	1.9	201
145	Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. Journal of Magnetic Resonance Imaging, 2009, 30, 444-448.	1.9	66
146	T ₁ independent, T ₂ * corrected MRI with accurate spectral modeling for quantification of fat: Validation in a fatâ€waterâ€6PIO phantom. Journal of Magnetic Resonance Imaging, 2009, 30, 1215-1222.	1.9	191
147	Noninvasive imaging biomarkers for steatosis assessment. Liver Transplantation, 2009, 15, 1389-1391.	1.3	7
148	Sources of hepatic triglyceride accumulation during highâ€ f at feeding in the healthy rat. NMR in Biomedicine, 2009, 22, 310-317.	1.6	53
149	Steatocholecystitis and Fatty Gallbladder Disease. Digestive Diseases and Sciences, 2009, 54, 1857-1863.	1.1	20
150	A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia, 2009, 52, 1056-1060.	2.9	256
151	Randomized controlled trial of the efficacy of aerobic exercise in reducing metabolic risk in healthy older people: The Hertfordshire Physical Activity Trial. BMC Endocrine Disorders, 2009, 9, 15.	0.9	10

#	Article	IF	CITATIONS
152	Alterations in Fatty Acid Kinetics in Obese Adolescents With Increased Intrahepatic Triglyceride Content. Obesity, 2009, 17, 25-29.	1.5	86
153	Ultrasonography to Quantify Hepatic Fat Content: Validation by ¹ H Magnetic Resonance Spectroscopy. Obesity, 2009, 17, 2239-2244.	1.5	40
154	Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy. Diabetes, Obesity and Metabolism, 2009, 11, 516-518.	2.2	3
155	Elevated fasting plasma Câ€peptide occurs in nonâ€diabetic individuals with fatty liver, irrespective of insulin resistance. Diabetic Medicine, 2009, 26, 847-854.	1.2	7
156	Nonalcoholic fatty liver disease: Quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. Journal of Digestive Diseases, 2009, 10, 315-320.	0.7	41
157	Liver fat and lipid oxidation in humans. Liver International, 2009, 29, 1439-1446.	1.9	89
158	Predictors of severe hepatic steatosis using abdominal ultrasound in HIVâ€infected patients. HIV Medicine, 2009, 10, 53-59.	1.0	28
159	Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy. European Radiology, 2009, 19, 1786-1793.	2.3	49
160	Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. European Radiology, 2009, 19, 2033-2040.	2.3	95
161	Parametric exploration of the liver by magnetic resonance methods. European Radiology, 2009, 19, 2594-2607.	2.3	35
162	Advanced MRI Methods for Assessment of Chronic Liver Disease. American Journal of Roentgenology, 2009, 193, 14-27.	1.0	169
163	In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 757-763.	1.2	35
164	Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 291-302.	1.1	266
165	Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. Journal of Hepatology, 2009, 50, 17-35.	1.8	177
166	Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. Journal of Hepatology, 2009, 51, 433-445.	1.8	667
167	Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery. Metabolism: Clinical and Experimental, 2009, 58, 753-758.	1.5	33
168	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Annals of Medicine, 2009, 41, 265-278.	1.5	108
169	Dietary Fat and Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction. Gastroenterology, 2009, 136, 1552-1560.	0.6	382

#	Article	IF	CITATIONS
170	Heritability of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2009, 136, 1585-1592.	0.6	419
171	Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors. Gastroenterology, 2009, 137, 865-872.	0.6	646
172	Recent advances in the pathophysiology of nephrolithiasis. Kidney International, 2009, 75, 585-595.	2.6	130
173	Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management. Clinics in Liver Disease, 2009, 13, 249-266.	1.0	55
174	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3842-3848.	1.8	164
175	Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T. Radiology, 2009, 251, 67-76.	3.6	287
176	Fatty Liver Disease: MR Imaging Techniques for the Detection and Quantification of Liver Steatosis. Radiographics, 2009, 29, 231-260.	1.4	246
177	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clinical Science, 2009, 116, 403-413.	1.8	30
180	New Imaging Techniques for Non-Alcoholic Steatohepatitis. Clinics in Liver Disease, 2009, 13, 607-619.	1.0	21
181	Methods for assessing intrahepatic fat content and steatosis. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 474-481.	1.3	42
182	Identification and Characterization of Metabolically Benign Obesity in Humans. Obstetrical and Gynecological Survey, 2009, 64, 30-31.	0.2	10
183	Metabolic disturbances in non-alcoholic fatty liver disease. Clinical Science, 2009, 116, 539-564.	1.8	210
184	The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clinical Science, 2009, 116, 531-537.	1.8	70
185	Magic angle spinning magnetic resonance: a novel method opening up translational research into NAFLD?. Clinical Science, 2009, 116, 401-402.	1.8	1
186	Non-Alcoholic Fatty Liver Disease. , 0, , 119-134.		4
187	Adipose Tissue and Metabolic Factors Associated With Steatosis in HIV/HCV Coinfection: Histology Versus Magnetic Resonance Spectroscopy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 228-231.	0.9	12
188	The importance of fatty liver disease in clinical practice. Proceedings of the Nutrition Society, 2010, 69, 518-527.	0.4	14
189	1Chapter 5 Intestinal Failure and Liver Disease Related to Parenteral Nutrition and Intestinal Transplantation. , 2010, , 251-270.		0

#	Article	IF	CITATIONS
190	Implications of diet on nonalcoholic fatty liver disease. Current Opinion in Gastroenterology, 2010, 26, 160-164.	1.0	53
191	Breath-Hold 1H-Magnetic Resonance Spectroscopy for Intrahepatic Lipid Quantification at 3 Tesla. Journal of Computer Assisted Tomography, 2010, 34, 372-376.	0.5	33
192	Strength Exercise Improves Muscle Mass and Hepatic Insulin Sensitivity in Obese Youth. Medicine and Science in Sports and Exercise, 2010, 42, 1973-1980.	0.2	136
193	Apolipoprotein B synthesis inhibition: results from clinical trials. Current Opinion in Lipidology, 2010, 21, 319-323.	1.2	35
195	Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease. Annual Review of Medicine, 2010, 61, 375-392.	5.0	77
196	The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia, 2010, 53, 882-889.	2.9	126
198	Nonalcoholic Fatty Liver Disease: A Review and Update. Digestive Diseases and Sciences, 2010, 55, 560-578.	1.1	287
199	Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey. BMC Public Health, 2010, 10, 237.	1.2	66
200	Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia. American Journal of Cardiology, 2010, 105, 1413-1419.	0.7	166
201	Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation. Journal of the American College of Surgeons, 2010, 210, 515-526.	0.2	34
202	Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology, 2010, 51, 679-689.	3.6	1,579
203	Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology, 2010, 52, 71-78.	3.6	47
204	Noninvasive quantification of hepatic steatosis inrats using 3.0 T ¹ Hâ€magnetic resonance spectroscopy. Journal of Magnetic Resonance Imaging, 2010, 32, 148-154.	1.9	31
205	Noise analysis for 3â€point chemical shiftâ€based waterâ€fat separation with spectral modeling of fat. Journal of Magnetic Resonance Imaging, 2010, 32, 493-500.	1.9	16
206	Independent estimation of <i>T</i> * ₂ for water and fat for improved accuracy of fat quantification. Magnetic Resonance in Medicine, 2010, 63, 849-857.	1.9	78
207	Nonalcoholic fatty liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 695-708.	1.0	158
208	A 12â€Week Aerobic Exercise Program Reduces Hepatic Fat Accumulation and Insulin Resistance in Obese, Hispanic Adolescents. Obesity, 2010, 18, 384-390.	1.5	198
209	The Relationship of Ectopic Lipid Accumulation to Cardiac and Vascular Function in Obesity and Metabolic Syndrome. Obesity, 2010, 18, 1116-1121.	1.5	35

CI	ΓΔΤΙ	REPORT	

#	Article	IF	CITATIONS
210	Downregulation of <i>ADIPOQ</i> and <i>PPARγ2</i> Gene Expression in Subcutaneous Adipose Tissue of Obese Adolescents With Hepatic Steatosis. Obesity, 2010, 18, 1911-1917.	1.5	33
211	Increased Wholeâ€Body Adiposity Without a Concomitant Increase in Liver Fat is Not Associated With Augmented Metabolic Dysfunction. Obesity, 2010, 18, 1510-1515.	1.5	78
212	Resistant starch improves insulin sensitivity in metabolic syndrome. Diabetic Medicine, 2010, 27, 391-397.	1.2	212
213	Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2010, , 201-206.		0
215	Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase. Sao Paulo Medical Journal, 2010, 128, 342-347.	0.4	8
216	Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World Journal of Gastroenterology, 2010, 16, 4784.	1.4	59
217	Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. American Journal of Clinical Nutrition, 2010, 92, 500-508.	2.2	59
218	Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1625-1628.	4.3	20
219	A Contract Research Organization's Challenge: Validating Cutting-Edge Software for Imaging in Clinical Studies. Drug Information Journal, 2010, 44, 719-725.	0.5	0
220	Specifically PNPLA3-Mediated Accumulation of Liver Fat in Obese Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E430-E436.	1.8	39
221	Effects of <i>PNPLA3</i> on Liver Fat and Metabolic Profile in Hispanic Children and Adolescents. Diabetes, 2010, 59, 3127-3130.	0.3	100
222	Relationships of Circulating Sex Hormone–Binding Globulin With Metabolic Traits in Humans. Diabetes, 2010, 59, 3167-3173.	0.3	130
223	Nonalcoholic Fatty Liver Disease as the Transducer of Hepatic Oversecretion of Very-Low-Density Lipoprotein–Apolipoprotein B-100 in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1043-1050.	1.1	52
224	Feasibility of Assessing Liver Lipid by Proton Magnetic Resonance Spectroscopy in Healthy Normal and Overweight Prepubertal Children. Diabetes Technology and Therapeutics, 2010, 12, 207-212.	2.4	12
225	Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterology, 2010, 1, 149-155.	0.9	7
226	The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology - Renal Physiology, 2010, 298, G440-G445.	1.6	132
227	Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. Journal of Lipid Research, 2010, 51, 1057-1062.	2.0	102
228	Environmental and Genetic Determinants of Fatty Liver in Humans. Digestive Diseases, 2010, 28, 169-178.	0.8	32

#	Article	IF	CITATIONS
229	The Effect of Lifestyle Changes in Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 267-273.	0.8	55
230	Assessment of Hepatic Steatosis in Patients Undergoing Liver Resection: Comparison of US, CT, T1-weighted Dual-Echo MR Imaging, and Point-resolved ¹ H MR Spectroscopy. Radiology, 2010, 256, 159-168.	3.6	286
231	Follow-up Whole-Body Assessment of Adipose Tissue Compartments during a Lifestyle Intervention in a Large Cohort at Increased Risk for Type 2 Diabetes. Radiology, 2010, 257, 353-363.	3.6	105
232	Nonalcoholic Fatty Liver Disease: Detection of Elevated Nicotinamide Adenine Dinucleotide Phosphate with in Vivo 3.0-T ³¹ P MR Spectroscopy with Proton Decoupling. Radiology, 2010, 256, 466-473.	3.6	48
233	C-reactive protein mediates the association of liver fat and carotid intima–media thickness in healthy men and men with the metabolic syndrome and/or uncomplicated type 2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2010, 4, 160-164.	1.8	1
234	Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 225-233.	1.2	108
235	Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?. Primary Care Diabetes, 2010, 4, 129-137.	0.9	56
236	Chronic Hepatitis C Is Associated With Peripheral Rather Than Hepatic Insulin Resistance. Gastroenterology, 2010, 138, 932-941.e3.	0.6	124
237	Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human Reproduction, 2010, 25, 212-220.	0.4	120
238	Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2010, 3, 121-137.	1.4	119
239	Hepatic lipid profiling in chronic hepatitis C: An in vitro and in vivo proton magnetic resonance spectroscopy study. Journal of Hepatology, 2010, 52, 16-24.	1.8	38
240	Non-invasive assessment of hepatic steatosis: Prospective comparison of the accuracy of imaging examinations. Journal of Hepatology, 2010, 52, 579-585.	1.8	311
241	Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: A break of intestinal insulin resistance?. Journal of Hepatology, 2010, 52, 952-953.	1.8	14
242	In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. Journal of Hepatology, 2010, 53, 732-737.	1.8	74
243	Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, 2010, 53, 934-940.	1.8	334
244	Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. European Journal of Radiology, 2010, 74, e60-e66.	1.2	50
245	Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. European Journal of Radiology, 2010, 75, e102-e107.	1.2	29
246	Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics, 2010, 57, 85-140.	0.5	40

#	Article	IF	CITATIONS
247	Splanchnic Balance of Free Fatty Acids, Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 139, 1961-1971.e1.	0.6	61
248	The Role of Non-Alcoholic Fatty Liver Disease in Cardiovascular Disease. Digestive Diseases, 2010, 28, 210-213.	0.8	54
249	Functional Magnetic Resonance Imaging of the Liver: Parametric Assessments Beyond Morphology. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 565-585.	0.6	10
250	Quantification of Liver Fat with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 337-357.	0.6	260
251	Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. Annals of Medicine, 2011, 43, 545-554.	1.5	46
252	Quantification of Hepatic Steatosis with T1-independent, T2*-corrected MR Imaging with Spectral Modeling of Fat: Blinded Comparison with MR Spectroscopy. Radiology, 2011, 258, 767-775.	3.6	345
253	Suboptimal maternal nutrition, during early fetal liver development, promotes lipid accumulation in the liver of obese offspring. Reproduction, 2011, 141, 119-126.	1.1	50
254	Non-invasive Quantification of Triglyceride Content in Steatotic Rat Livers by 1H-MRS. Academic Radiology, 2011, 18, 1582-1592.	1.3	12
255	Hepatic fat-content assessment using magnetic resonance-based methods. Imaging in Medicine, 2011, 3, 193-206.	0.0	4
256	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113.	2.7	253
256 257	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523.	2.7 6.0	253 1,780
256 257 258	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225.	2.7 6.0 1.4	253 1,780 30
256 257 258 259	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649.	2.7 6.0 1.4 1.5	253 1,780 30 1,098
256 257 258 259 260	 Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study. Journal of Alternative and Complementary Medicine, 2011, 17, 413-420. 	2.7 6.0 1.4 1.5 2.1	253 1,780 30 1,098 22
255 257 258 259 260 261	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study. Journal of Alternative and Complementary Medicine, 2011, 17, 413-420. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology, 2011, 54, 153-159.	2.7 6.0 1.4 1.5 2.1 1.8	253 1,780 30 1,098 22 123
255 257 258 259 260 261	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study. Journal of Alternative and Complementary Medicine, 2011, 17, 413-420. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology, 2011, 54, 153-159. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 666-672.	2.7 6.0 1.4 1.5 2.1 1.8 1.8	253 1,780 30 1,098 22 123 318
255 257 258 259 260 261 262	Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 97-113. Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 2011, 43, 617-649. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study. Journal of Alternative and Complementary Medicine, 2011, 17, 413-420. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology, 2011, 54, 153-159. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 666-672. Associations of Visceral and Liver Fat With the Metabolic Syndrome Across the Spectrum of Obesity: The AGESa€Reykjavik Study. Obesity, 2011, 19, 1265-1271.	2.7 6.0 1.4 1.5 2.1 1.8 1.8 1.5	2253 1,780 30 1,098 22 123 123 318

#	ARTICLE	IF	CITATIONS
265	Liver MR imaging at 3T: challenges and opportunities. , 0, , 67-81.		0
266	Non-Invasive Assessment of the Liver $\hat{a} \in \mathcal{C}$ Serum Markers and Imaging Techniques. , 0, , .		2
267	Comparison of 1H MR Spectroscopy, 3-point DIXON, and Multi-echo Gradient Echo for Measuring Hepatic Fat Fraction. Magnetic Resonance in Medical Sciences, 2011, 10, 41-48.	1.1	20
268	Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study. PLoS ONE, 2011, 6, e24895.	1.1	82
269	Antisense Oligonucleotides for the Treatment of Dyslipidemia. Current Pharmaceutical Design, 2011, 17, 950-960.	0.9	18
271	Potential of Electron Beam Computed Tomography for Coronary Artery Calcium Screening to Evaluate Fatty Liver: Comparison with 1H Magnetic Resonance Spectroscopy in the Dallas Heart Study. Journal of Investigative Medicine, 2011, 59, 780-786.	0.7	4
272	Elevation of liver enzymes within the normal limits and metabolic syndrome. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 373-379.	0.9	29
273	Psoriasis and nonâ€ e lcoholic fatty liver disease. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 383-391.	1.3	55
274	Comparison of the Relative Contributions of Intraâ€Abdominal and Liver Fat to Components of the Metabolic Syndrome. Obesity, 2011, 19, 23-28.	1.5	58
275	Histopathological evaluation of fatty and alcoholic liver diseases. Journal of Digestive Diseases, 2011, 12, 17-24.	0.7	24
276	Pathophysiology and clinical management of non-alcoholic fatty liver disease. Medicine, 2011, 39, 592-596.	0.2	3
277	The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. European Radiology, 2011, 21, 87-97.	2.3	439
278	Simultaneous assessment of liver volume and whole liver fat content: a step towards one-stop shop preoperative MRI protocol. European Radiology, 2011, 21, 301-309.	2.3	20
279	Assessment of relevant hepatic steatosis in obese adolescents by rapid fat-selective GRE imaging with spatial-spectral excitation: a quantitative comparison with spectroscopic findings. European Radiology, 2011, 21, 816-822.	2.3	9
280	Chemotherapy-Associated Liver Injury: Impact on Surgical Management of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2011, 18, 181-190.	0.7	54
281	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature Reviews Endocrinology, 2011, 7, 456-465.	4.3	272
282	Mitochondrial diabetes is associated with insulin resistance in subcutaneous adipose tissue but not with increased liver fat content. Journal of Inherited Metabolic Disease, 2011, 34, 1205-1212.	1.7	7
283	The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. Journal of Neurology, 2011, 258, 1987-1997.	1.8	87

#	Article	IF	CITATIONS
284	MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 297-304.	1.1	27
285	1Hâ^'MRS of hepatic fat using short TR at 3T: SNR optimization and fast T2 relaxometry. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 339-345.	1.1	11
286	Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia, 2011, 54, 2506-2514.	2.9	909
287	Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine, 2011, 40, 332-343.	1.1	57
288	Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities. Frontiers of Medicine, 2011, 5, 288-293.	1.5	7
289	Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transplantation, 2011, 17, 189-200.	1.3	42
290	Liver methylene fraction by dual―and tripleâ€echo gradientâ€echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration. Journal of Magnetic Resonance Imaging, 2011, 33, 119-127.	1.9	12
291	T ₁ independent, T ₂ [*] corrected chemical shift based fat–water separation with multiâ€peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. Journal of Magnetic Resonance Imaging, 2011, 33, 873-881.	1.9	183
292	Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. Journal of Magnetic Resonance Imaging, 2011, 34, 729-749.	1.9	613
293	Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: Validation in phantoms and in patients with chronic liver disease. Journal of Magnetic Resonance Imaging, 2011, 33, 1390-1398.	1.9	55
294	Reproducibility of MRIâ€determined proton density fat fraction across two different MR scanner platforms. Journal of Magnetic Resonance Imaging, 2011, 34, 928-934.	1.9	130
295	Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. Journal of Magnetic Resonance Imaging, 2011, 34, 729-749.	1.9	359
296	Combination of complexâ€based and magnitudeâ€based multiecho waterâ€ f at separation for accurate quantification of fatâ€fraction. Magnetic Resonance in Medicine, 2011, 66, 199-206.	1.9	166
297	Longâ€₹E ¹ H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. NMR in Biomedicine, 2011, 24, 238-245.	1.6	62
298	<i>In vivo</i> characterization of the liver fat ¹ H MR spectrum. NMR in Biomedicine, 2011, 24, 784-790.	1.6	452
299	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology, 2011, 53, 448-457.	3.6	261
300	Dissociation between <i>APOC3</i> variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011, 53, 467-474.	3.6	122
301	Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology, 2011, 53, 1504-1514.	3.6	246

		LPORT	
#	Article	IF	CITATIONS
302	Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology, 2011, 54, 344-353.	3.6	617
303	Hepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in Nieman Pick C1-like 1. Hepatology, 2011, 54, 736-737.	3.6	2
304	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology, 2011, 54, 837-845.	3.6	74
305	Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutrition and Diabetes, 2011, 1, e6-e6.	1.5	152
306	Hepatic Steatosis in Morbidly Obese Patients Undergoing Gastric Bypass Surgery: Assessment With Open-System ¹ H-MR Spectroscopy. American Journal of Roentgenology, 2011, 196, W736-W742.	1.0	18
307	Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T. Radiology, 2011, 258, 749-759.	3.6	259
308	Three Weeks on a High-Fat Diet Increases Intrahepatic Lipid Accumulation and Decreases Metabolic Flexibility in Healthy Overweight Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E691-E695.	1.8	98
309	Diabetes Revealed: Multisystem Danger. American Journal of Roentgenology, 2011, 196, 274-286.	1.0	2
310	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs, 2011, 16, 121-136.	1.0	18
311	Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. American Journal of Clinical Nutrition, 2011, 93, 1048-1052.	2.2	261
312	Lipids in the Wrong Place: Visceral Fat and Nonalcoholic Steatohepatitis. Diabetes Care, 2011, 34, S367-S370.	4.3	37
313	Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut, 2011, 60, 1278-1283.	6.1	382
314	Bariatric Surgery and Cardiovascular Risk Factors. Circulation, 2011, 123, 1683-1701.	1.6	279
315	Quantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and 1H-MR spectroscopy. Journal of Lipid Research, 2011, 52, 1847-1855.	2.0	30
316	Assessing Adiposity. Circulation, 2011, 124, 1996-2019.	1.6	701
317	Update on liver MRI at 3T. Imaging in Medicine, 2011, 3, 51-65.	0.0	3
318	Recent advances in imaging hepatic fibrosis and steatosis. Expert Review of Gastroenterology and Hepatology, 2011, 5, 91-104.	1.4	15
319	Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney International, 2011, 79, 228-233.	2.6	55

#	ARTICLE	IF	CITATIONS
320	Computer-Aided UltraSound (CAUS) to determine liver fat content in animal model and in patients. , 2011, , .		0
321	Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats. Acta Radiologica, 2011, 52, 658-664.	0.5	7
322	Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. International Journal of Endocrinology, 2012, 2012, 1-18.	0.6	231
323	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut, 2012, 61, 409-415.	6.1	423
324	Effects of Lipid Regulation Using Raw and Processed Radix Polygoni Multiflori in Rats Fed a High-Fat Diet. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	19
325	Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. European Journal of Endocrinology, 2012, 166, 993-1002.	1.9	45
326	Excess body fat in obese and normal-weight subjects. Nutrition Research Reviews, 2012, 25, 150-161.	2.1	130
327	Adipose Tissue Biology and Cardiomyopathy. Circulation Research, 2012, 111, 1565-1577.	2.0	70
328	Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3709-3716.	1.8	198
329	Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 236-246.	1.1	35
330	Graft fibrosis and recipient survival in postorthotopic liver transplant nonalcoholic fatty liver disease. Egyptian Liver Journal, 2012, 2, 1-6.	0.3	0
331	Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. European Journal of Endocrinology, 2012, 166, 487-492.	1.9	32
332	MRI Steatosis Grading: Development and Initial Validation of a Color Mapping System. American Journal of Roentgenology, 2012, 198, 582-588.	1.0	48
333	Pancreatic Steatosis and Its Relationship to β-Cell Dysfunction in Humans. Diabetes Care, 2012, 35, 2377-2383.	4.3	102
334	MR Imaging Evaluation of Cardiovascular Risk in Metabolic Syndrome. Radiology, 2012, 264, 21-37.	3.6	47
335	Evaluating Childhood Obesity: Magnetic Resonance-Based Quantification of Abdominal Adipose Tissue and Liver Fat in Children. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2012, 184, 324-332.	0.7	7
336	US Cannot Be Used to Predict the Presence or Severity of Hepatic Steatosis in Severely Obese Adolescents. Radiology, 2012, 262, 327-334.	3.6	55
337	Measurement of blood flow and xenon solubility coefficient in the human liver by xenonâ€enhanced computed tomography. Medical Physics, 2012, 39, 7553-7559.	1.6	5

#	Article	IF	CITATIONS
338	Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. Journal of Applied Physiology, 2012, 113, 1-6.	1.2	83
339	Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. Seminars in Liver Disease, 2012, 32, 065-079.	1.8	53
340	WAT is a functional adipocyte?. Adipocyte, 2012, 1, 38-45.	1.3	24
341	Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Care, 2012, 35, 873-878.	4.3	214
342	Hepatocyte-specific Deletion of Janus Kinase 2 (JAK2) Protects against Diet-induced Steatohepatitis and Glucose Intolerance. Journal of Biological Chemistry, 2012, 287, 10277-10288.	1.6	58
343	The Interaction of rs738409, Obesity, and Alcohol: A Population-Based Autopsy Study. American Journal of Gastroenterology, 2012, 107, 1668-1674.	0.2	23
344	Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. American Journal of Clinical Nutrition, 2012, 96, 727-734.	2.2	171
345	Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. Scientifica, 2012, 2012, 1-21.	0.6	10
346	Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target. Journal of Lipids, 2012, 2012, 1-8.	1.9	88
347	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 2012, 1-12.	3.8	182
348	Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude. World Journal of Gastroenterology, 2012, 18, 3889.	1.4	60
349	Hydrogen-1 MR Spectroscopy for Measurement and Diagnosis of Hepatic Steatosis. American Journal of Roentgenology, 2012, 199, 2-7.	1.0	46
350	Nonalcoholic fatty liver disease and lipids. Current Opinion in Lipidology, 2012, 23, 345-352.	1.2	49
351	Hepatic Fat Quantification. Investigative Radiology, 2012, 47, 368-375.	3.5	98
352	Quantification of Hepatic Steatosis With Dual-Energy Computed Tomography. Investigative Radiology, 2012, 47, 603-610.	3.5	72
353	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. Current Vascular Pharmacology, 2012, 10, 162-172.	0.8	42
354	lsoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. International Journal of Molecular Medicine, 2012, 30, 1241-1249.	1.8	22
355	Effect of Insulin versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes. Journal of Investigative Medicine, 2012, 60, 1059-1063.	0.7	11

#	Article	IF	CITATIONS
356	Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method. Obesity, 2012, 20, 444-452.	1.5	116
358	Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. European Radiology, 2012, 22, 2161-2168.	2.3	21
359	Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: The Shanghai Changfeng study. Atherosclerosis, 2012, 224, 480-485.	0.4	42
360	Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes. Atherosclerosis, 2012, 224, 465-468.	0.4	9
361	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. European Heart Journal, 2012, 33, 1190-1200.	1.0	372
362	High Rates of Fructose Malabsorption Are Associated with Reduced Liver Fat in Obese African Americans. Journal of the American College of Nutrition, 2012, 31, 369-374.	1.1	34
363	Intravoxel Incoherent Motion Diffusion-weighted Imaging in Nonalcoholic Fatty Liver Disease: A 3.0-T MR Study. Radiology, 2012, 265, 96-103.	3.6	148
364	Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. Journal of Hepatology, 2012, 56, 255-266.	1.8	443
365	The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. Journal of Hepatology, 2012, 56, 640-646.	1.8	21
366	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology, 2012, 56, 1363-1370.	1.8	198
367	Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 2012, 57, 157-166.	1.8	390
368	Susceptibility Variants for Waist Size in Relation to Abdominal, Visceral, and Hepatic Adiposity in Postmenopausal Women. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 1048-1055.	0.4	11
369	Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 809-818.	1.2	229
370	Metabolic insights from extreme human insulin resistance phenotypes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 145-157.	2.2	28
371	MR spectroscopy of liver in overweight children and adolescents: Investigation of 1H T2 relaxation times at 3T. European Journal of Radiology, 2012, 81, 811-814.	1.2	21
372	Nonâ€alcoholic fatty liver disease. Journal of Diabetes, 2012, 4, 266-280.	0.8	46
373	Assessment of nonâ€elcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology and Therapeutics, 2012, 36, 1057-1066.	1.9	61
374	Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2012, 16, 397-419.	1.0	58

#	Article	IF	CITATIONS
375	Metformin use in children with obesity and normal glucose tolerance – effects on cardiovascular markers and intrahepatic fat. Journal of Pediatric Endocrinology and Metabolism, 2012, 25, 33-40.	0.4	52
376	Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2012, 2, 145-155.	0.4	36
377	Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0T before hepatic surgery: Reliable enough for making clinical decisions?. European Journal of Radiology, 2012, 81, 2990-2995.	1.2	15
378	VO(dmpp)2 normalizes pre-diabetic parameters as assessed by in vivo magnetic resonance imaging and spectroscopy. Journal of Inorganic Biochemistry, 2012, 115, 44-49.	1.5	30
379	Quelle place pour le traitement par pompe à insuline externe dans le diabète de type 2 ?. Medecine Des Maladies Metaboliques, 2012, 6, 429-433.	0.1	0
380	Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clinical Nutrition, 2012, 31, 520-525.	2.3	36
381	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. European Heart Journal, 2012, 33, 1142-1149.	1.0	171
382	Predicting Total, Abdominal, Visceral and Hepatic Adiposity with Circulating Biomarkers in Caucasian and Japanese American Women. PLoS ONE, 2012, 7, e43502.	1.1	51
383	The Relationship between Nonalcoholic Fatty Liver Disease and Colorectal Cancer: The Future Challenges and Outcomes of the Metabolic Syndrome. Journal of Obesity, 2012, 2012, 1-8.	1.1	38
384	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists?. Journal of Obesity, 2012, 2012, 1-9.	1.1	73
385	Regional differences in hepatic fat fractions in over- weight children and adolescents observed by 3T 1H-MR spectroscopy. Journal of Biomedical Graphics and Computing, 2012, 3, .	0.2	0
386	Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. Journal of Gastroenterology, 2012, 47, 1014-1021.	2.3	17
387	Liverâ€vessel cancellation artifact on inâ€phase and outâ€ofâ€phase MRI imaging: A sign of ultraâ€high liver fat content. Journal of Magnetic Resonance Imaging, 2012, 35, 1112-1118.	1.9	4
388	Addressing phase errors in fatâ€water imaging using a mixed magnitude/complex fitting method. Magnetic Resonance in Medicine, 2012, 67, 638-644.	1.9	105
389	Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. European Radiology, 2012, 22, 855-863.	2.3	29
390	Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. European Journal of Applied Physiology, 2012, 112, 1817-1825.	1.2	14
391	Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutrition Reviews, 2012, 70, 41-56.	2.6	104
392	The diagnosis of nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2012, 35, 204-205.	1.9	11

#	Article	IF	CITATIONS
393	Epicardial Fat, Cardiac Dimensions, and Low-Grade Inflammation in Young Adult Monozygotic Twins Discordant for Obesity. American Journal of Cardiology, 2012, 109, 1295-1302.	0.7	39
394	Effect of baicalin on toll-like receptor 4-mediated ischemia/reperfusion inflammatory responses in alcoholic fatty liver condition. Toxicology and Applied Pharmacology, 2012, 258, 43-50.	1.3	49
395	Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma. European Journal of Clinical Investigation, 2012, 42, 1165-1172.	1.7	11
396	Genetic variation in <i>PNPLA3</i> but not <i>APOC3</i> influences liver fat in nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 951-956.	1.4	49
397	Assessment of inflammation and fibrosis in nonâ€alcoholic fatty liver disease by imagingâ€based techniques. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1281-1292.	1.4	30
398	On the performance of <i>T</i> ₂ * correction methods for quantification of hepatic fat content. Magnetic Resonance in Medicine, 2012, 67, 389-404.	1.9	44
399	Alterations in Ventricular Structure and Function in Obese Adolescents with Nonalcoholic Fatty Liver Disease. Journal of Pediatrics, 2013, 162, 1160-1168.e1.	0.9	59
400	Variability in fasting lipid and glycogen contents in hepatic and skeletal muscle tissue in subjects with and without type 2 diabetes: a ¹ H and ¹³ C MRS study. NMR in Biomedicine, 2013, 26, 1518-1526.	1.6	24
401	Other Diffuse Liver Diseases: Steatosis, Hemochromatosis, etc , 2013, , 1027-1044.		2
402	Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver. Diabetes Care, 2013, 36, 2331-2338.	4.3	100
403	Brain Insulin and Leptin Signaling in Metabolic Control. Endocrinology and Metabolism Clinics of North America, 2013, 42, 109-125.	1.2	12
404	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia, 2013, 56, 2266-2274.	2.9	129
405	Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia, 2013, 56, 886-892.	2.9	48
406	Diagnosis and management of nonâ€alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the <scp>S</scp> tudy <scp>G</scp> roup of <scp>L</scp> iver and <scp>M</scp> etabolism, <scp>C</scp> hinese <scp>S</scp> ociety of <scp>E</scp> ndocrinology (éžé'ç ²³ /æ€	§è",,e,ªæ€	§è, ç —ä,Ž <mark>¢</mark> ,
407	1H MRS assessment of hepatic steatosis in overweight children and adolescents: comparison between 3T and open 1T MR-systems. Abdominal Imaging, 2013, 38, 315-319.	2.0	18
408	Liver fat volume fraction quantification with fat and water T1 and T2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. European Radiology, 2013, 23, 2175-2186.	2.3	29
409	Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. European Radiology, 2013, 23, 1643-1649.	2.3	19
410	Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology, 2013, 58, 1930-1940.	3.6	434

0			n	
	ΙΤΔΤ	$1 \cap N$	INE	DUBL
<u> </u>	/			

#	Article	IF	CITATIONS
411	Correlation between Hepatic Fat Content Using 3-Echo 3-D Dixon Method and Intravoxel Incoherent Motion (IVIM) Perfusion MR Imaging. Applied Magnetic Resonance, 2013, 44, 791-801.	0.6	6
412	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Annals of the New York Academy of Sciences, 2013, 1281, 106-122.	1.8	216
413	Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and Intralipid solutions and correlation to insulin levels. Metabolism: Clinical and Experimental, 2013, 62, 1850-1857.	1.5	17
414	Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology, 2013, 58, 1287-1295.	3.6	275
415	Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 666-675.	8.2	238
416	Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection, 2013, 19, 338-348.	2.8	196
417	11β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue Glucocorticoid Action. Physiological Reviews, 2013, 93, 1139-1206.	13.1	659
418	Functional Imaging of the Liver. Seminars in Ultrasound, CT and MRI, 2013, 34, 54-65.	0.7	13
419	Nrf2 deletion causes "benign―simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids in Health and Disease, 2013, 12, 165.	1.2	63
420	Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype. Obesity, 2013, 21, 1174-1179.	1.5	19
421	Autophagy Deficiency by Hepatic FIP200 Deletion Uncouples Steatosis From Liver Injury in NAFLD. Molecular Endocrinology, 2013, 27, 1643-1654.	3.7	95
422	R2* estimation using "inâ€phase―echoes in the presence of fat: The effects of complex spectrum of fat. Journal of Magnetic Resonance Imaging, 2013, 37, 717-726.	1.9	40
423	Liver fat content is linked to inflammatory changes in subcutaneous adipose tissue in type 2 diabetes patients. Clinical Endocrinology, 2013, 79, 661-666.	1.2	7
424	Genetic and clinical markers of elevated liver fat content in overweight and obese hispanic children. Obesity, 2013, 21, E790-7.	1.5	12
425	A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis. ACS Chemical Biology, 2013, 8, 559-567.	1.6	92
426	Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis. European Radiology, 2013, 23, 461-467.	2.3	35
427	Comparison of <i>R</i> ₂ * correction methods for accurate fat quantification in fatty liver. Journal of Magnetic Resonance Imaging, 2013, 37, 414-422.	1.9	47
428	Fat confounds the observed apparent diffusion coefficient in patients with hepatic steatosis. Magnetic Resonance in Medicine, 2013, 69, 545-552.	1.9	39

#	Article	IF	CITATIONS
429	Diagnostic imaging in obesity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 261-277.	2.2	35
430	Cardiac Steatosis and Left Ventricular Hypertrophy in Patients WithÂGeneralized Lipodystrophy as Determined by Magnetic Resonance Spectroscopy and Imaging. American Journal of Cardiology, 2013, 112, 1019-1024.	0.7	59
431	Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, e279-e285.	0.6	104
432	Investigation of 1H MRS for quantification of hepatic triglyceride in lean and obese cats. Research in Veterinary Science, 2013, 95, 678-680.	0.9	13
433	MR Fat Fraction Mapping. Academic Radiology, 2013, 20, 957-961.	1.3	5
434	Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. American Journal of Physiology - Renal Physiology, 2013, 305, G483-G495.	1.6	232
435	MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes and Metabolism, 2013, 39, 314-321.	1.4	18
436	Nonalcoholic fatty liver disease and serum lipoproteins: TheÂMulti-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013, 227, 429-436.	0.4	158
437	From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology, 2013, 59, 859-871.	1.8	304
438	Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. Journal of Hepatology, 2013, 59, 557-562.	1.8	186
439	Intrahepatic Fat Is Increased in the Neonatal Offspring of Obese Women with Gestational Diabetes. Journal of Pediatrics, 2013, 162, 930-936.e1.	0.9	164
440	Quantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T 2 correction: phantom and clinical study with histologic assessment. Radiological Physics and Technology, 2013, 6, 219-225.	1.0	19
441	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 330-344.	8.2	1,381
442	Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. British Journal of Pharmacology, 2013, 168, 339-353.	2.7	58
443	Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population. Diabetic Medicine, 2013, 30, 428-435.	1.2	38
444	Magnetic Resonance Imaging in Pharmaceutical Safety Assessment. , 2013, , 561-571.		1
445	Obesity Phenotypes: Measures to Assess Adipose Tissue Mass in Humans. , 2013, , 243-253.		2
446	Modern Imaging Evaluation of the Liver. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 337-363.	0.6	6

#	Article	IF	CITATIONS
447	Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis. Radiology, 2013, 267, 422-431.	3.6	410
448	Improved Hepatic Lipid Composition Following Short-Term Exercise in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1181-E1188.	1.8	76
449	The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 59, 138-143.	1.8	580
450	Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1540-E1548.	1.8	23
451	Whole body fat: Content and distribution. Progress in Nuclear Magnetic Resonance Spectroscopy, 2013, 73, 56-80.	3.9	109
452	The genetics of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 645-655.	8.2	297
453	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a ¹ H MRS study. NMR in Biomedicine, 2013, 26, 204-212.	1.6	5
454	The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetology and Metabolic Syndrome, 2013, 5, 35.	1.2	11
455	Liver Fat Has a Stronger Association With Risk Factors for Type 2 Diabetes in African-American Compared With Hispanic Adolescents. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3748-3754.	1.8	23
456	Renal Lipids and Oxygenation in Diabetic Mice: Noninvasive Quantification with MR Imaging. Radiology, 2013, 269, 748-757.	3.6	37
457	Cardiac Steatosis Associates With Visceral Obesity in Nondiabetic Obese Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1189-1197.	1.8	98
458	Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews, 2013, 34, 84-129.	8.9	197
459	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterology Research and Practice, 2013, 2013, 1-8.	0.7	42
460	Intrahepatic Lipid Content and Insulin Resistance Are More Strongly Associated with Impaired NEFA Suppression after Oral Glucose Loading Than with Fasting NEFA Levels in Healthy Older Individuals. International Journal of Endocrinology, 2013, 2013, 1-7.	0.6	3
461	Jiao Tai Wan Attenuates Hepatic Lipid Accumulation in Type 2 Diabetes Mellitus. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	18
462	Beneficial Effects of an 8-Week, Very Low Carbohydrate Diet Intervention on Obese Subjects. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-8.	0.5	26
463	In vivo hepatic lipid quantification using MRS at 7 Tesla in a mouse model of glycogen storage disease type 1a. Journal of Lipid Research, 2013, 54, 2010-2022.	2.0	14
464	Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E879-E889.	1.8	28

#	Article	IF	CITATIONS
465	CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. American Journal of Physiology - Renal Physiology, 2013, 305, G214-G224.	1.6	105
466	Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. European Journal of Endocrinology, 2013, 168, 771-778.	1.9	15
467	Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2013, 14, 19867-19890.	1.8	56
468	Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E50-E58.	1.8	54
469	Exercise Training in Polycystic Ovarian Syndrome Enhances Flow-Mediated Dilation in the Absence of Changes in Fatness. Medicine and Science in Sports and Exercise, 2013, 45, 2234-2242.	0.2	38
470	Exercise and Type 2 Diabetes Mellitus: Changes in Tissue-specific Fat Distribution and Cardiac Function. Radiology, 2013, 269, 434-442.	3.6	47
471	Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy. Radiology, 2013, 267, 767-775.	3.6	314
472	Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut, 2013, 62, 1625-1633.	6.1	87
473	Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean Journal of Internal Medicine, 2013, 28, 439.	0.7	9
474	Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. British Journal of Nutrition, 2013, 109, 1096-1104.	1.2	69
475	Rapid Improvement of Hepatic Steatosis after Initiation of Leptin Substitution in a Leptin-Deficient Girl. Hormone Research in Paediatrics, 2013, 79, 310-317.	0.8	37
476	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology, 2013, 66, 1033-1045.	1.0	70
477	Liver fat and SHBC affect insulin resistance in midlife women: The Study of Women's Health Across the Nation (SWAN). Obesity, 2013, 21, 1031-1038.	1.5	32
478	Intrahepatic lipid, not visceral or muscle fat, is correlated with insulin resistance in older, female rhesus macaques. Obesity, 2013, 21, 2021-2028.	1.5	4
479	Impact of vitamin <scp>D</scp> insufficiency on insulin homeostasis and beta cell function in nondiabetic male <scp>HIV</scp> â€infected patients. HIV Medicine, 2013, 14, 540-548.	1.0	12
480	Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2013, 37, 1359-1370.	1.9	68
481	Ultrasound Evaluation and Correlates of Fatty Liver Disease: A Population Study in a Mediterranean Area. Metabolic Syndrome and Related Disorders, 2013, 11, 349-358.	0.5	25
482	Steatosis in the Liver. , 2013, 3, 1493-1532.		33

#	Article	IF	CITATIONS
483	Organ Size Increases With Weight Gain in Power-Trained Athletes. International Journal of Sport Nutrition and Exercise Metabolism, 2013, 23, 617-623.	1.0	12
485	In vivo ¹ H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: An animal study at 9.4 T. Magnetic Resonance in Medicine, 2013, 70, 620-629.	1.9	14
486	Multipeak fatâ€corrected complex R2* relaxometry: Theory, optimization, and clinical validation. Magnetic Resonance in Medicine, 2013, 70, 1319-1331.	1.9	115
487	Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clinical Lipidology, 2013, 8, 411-418.	0.4	27
488	Measuring Visceral and Hepatic Fat in Clinical Practice and Clinical Research. Endocrine Practice, 2013, 19, 587-595.	1.1	17
489	Diagnostic Performance of a Rapid Magnetic Resonance Imaging Method of Measuring Hepatic Steatosis. PLoS ONE, 2013, 8, e59287.	1.1	10
490	Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) of 3.0T in assessment of steatosis to antiviral therapy for chronic hepatitis C. African Journal of Biotechnology, 2014, 13, 4753-4760.	0.3	0
491	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. PLoS ONE, 2014, 9, e91987.	1.1	130
492	Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance. PLoS ONE, 2014, 9, e94059.	1.1	124
493	Triglycerides in the Human Kidney Cortex: Relationship with Body Size. PLoS ONE, 2014, 9, e101285.	1.1	58
494	The Potential of a High Protein-Low Carbohydrate Diet to Preserve Intrahepatic Triglyceride Content in Healthy Humans. PLoS ONE, 2014, 9, e109617.	1.1	16
495	Is MR Spectroscopy Really the Best MR-Based Method for the Evaluation of Fatty Liver in Diabetic Patients in Clinical Practice?. PLoS ONE, 2014, 9, e112574.	1.1	23
496	Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-20.	1.9	120
497	Radiologic evaluation of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 7392.	1.4	330
498	Fatty liver in childhood. World Journal of Hepatology, 2014, 6, 33.	0.8	11
499	Definition, Pathogenesis, and Natural Progress of Non-alcoholic Fatty Liver Disease. Journal of Korean Diabetes, 2014, 15, 65.	0.1	5
500	YKL-40 is a Protective Biomarker for Fatty Liver in World Trade Center Particulate Matter-Exposed Firefighters. Journal of Molecular Biomarkers & Diagnosis, 2014, 05, .	0.4	9
501	Nonalcoholic fatty liver disease and polycystic ovary syndrome. World Journal of Gastroenterology, 2014, 20, 8351.	1.4	128

#	Article	IF	CITATIONS
502	Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology, 2014, 20, 12956.	1.4	154
503	The Metabolic Syndrome and Chronic Liver Disease. Current Pharmaceutical Design, 2014, 20, 5010-5024.	0.9	35
505	Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1298-H1306.	1.5	101
506	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. Digestive Diseases, 2014, 32, 586-596.	0.8	10
507	Apolipoprotein C3 Gene Polymorphisms Are Not a Risk Factor for Developing Non-Alcoholic Fatty Liver Disease: A Meta-Analysis. Hepatitis Monthly, 2014, 14, e23100.	0.1	18
508	Reducing Liver Fat by Low Carbohydrate Caloric Restriction Targets Hepatic Glucose Production in Non-Diabetic Obese Adults with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2014, 3, 1050-1063.	1.0	25
509	Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. American Journal of Physiology - Renal Physiology, 2014, 307, G760-G768.	1.6	24
510	Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clinical Science, 2014, 126, 67-74.	1.8	32
511	Role of Mitochondria in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2014, 15, 8713-8742.	1.8	271
512	Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 2014, 4, e004973.	0.8	74
513	Modulation of Amino Acid Metabolic Signatures by Supplemented Isoenergetic Diets Differing in Protein and Cereal Fiber Content. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2599-E2609.	1.8	32
514	Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. Journal of Magnetic Resonance Imaging, 2014, 39, 1525-1532.	1.9	85
515	Hepatic steatosis: Effect on hepatocyte enhancement with gadoxetate disodiumâ€enhanced liver MR imaging. Journal of Magnetic Resonance Imaging, 2014, 39, 42-50.	1.9	13
516	Ethnic differences in the effects of hepatic fat deposition on insulin resistance in nonobese middle school girls. Obesity, 2014, 22, 243-248.	1.5	11
517	Quantification of the triglyceride fatty acid composition with 3.0 T MRI. NMR in Biomedicine, 2014, 27, 1211-1221.	1.6	54
518	Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study. Hepatology, 2014, 60, 1211-1221.	3.6	263
519	Fat fraction bias correction using T ₁ estimates and flip angle mapping. Journal of Magnetic Resonance Imaging, 2014, 39, 217-223.	1.9	20
520	Relationships of body composition and liver fat content with insulin resistance in obesityâ€matched adolescents and adults. Obesity, 2014, 22, 1325-1331.	1.5	35

	CITATION	n Report	
#	Article	IF	CITATIONS
521	Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian Journal of Gastroenterology, 2014, 33, 452-457.	0.7	57
522	Quantification of hepatic steatosis: A comparison of the accuracy among multiple magnetic resonance techniques. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 807-813.	1.4	32
523	External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. European Journal of Endocrinology, 2014, 171, 561-569.	1.9	126
524	Imaging Techniques for Partial Grafting. , 2014, , 634-641.		0
525	Fat and Iron Quantification in the Liver. Topics in Magnetic Resonance Imaging, 2014, 23, 73-94.	0.7	43
526	Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal Malignancies. Postgraduate Medicine, 2014, 126, 106-118.	0.9	14
527	Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation. Clinical Endocrinology, 2014, 81, 855-861.	1.2	21
528	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open, 2014, 4, e005325.	0.8	52
529	Long-Term Risperidone Treatment Induces Visceral Adiposity Associated with Hepatic Steatosis in Mice: A Magnetic Resonance Approach. Schizophrenia Research and Treatment, 2014, 2014, 1-11.	0.7	8
530	Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2092-2103.e6.	2.4	237
531	Quantification of Hepatic Steatosis. Academic Radiology, 2014, 21, 507-513.	1.3	20
532	Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors?. Arab Journal of Gastroenterology, 2014, 15, 12-15.	0.4	45
533	Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncológica, 2014, 53, 351-360.	0.8	32
534	New and Improved Imaging Modalities for NAFLD. Current Hepatology Reports, 2014, 13, 88-96.	0.4	1
535	Epidemiology and clinical pathophysiology of uric acid kidney stones. Journal of Nephrology, 2014, 27, 241-245.	0.9	78
536	Measuring liver triglyceride content in mice: non-invasive magnetic resonance methods as an alternative to histopathology. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 317-327.	1.1	19
537	Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014, 46, 352-356.	9.4	938
538	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal, 2014, 90, 254-266.	0.9	12

#	Article	IF	CITATIONS
539	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 161-167.	1.5	69
540	Energy metabolism and fertility—a balance preserved for female health. Nature Reviews Endocrinology, 2014, 10, 13-23.	4.3	101
541	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology, 2014, 59, 2178-2187.	3.6	129
542	The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2085-2091.e1.	2.4	237
543	Initial clinical application of modified Dixon with flexible echo times: hepatic and pancreatic fat assessments in comparison with 1H MRS. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2014, 27, 397-405.	1.1	34
544	Eradicating hepatitis <scp>C</scp> virus ameliorates insulin resistance without change in adipose depots. Journal of Viral Hepatitis, 2014, 21, 325-332.	1.0	22
545	Sterol Regulatory Element-binding Protein-1 (SREBP-1) Is Required to Regulate Glycogen Synthesis and Gluconeogenic Gene Expression in Mouse Liver. Journal of Biological Chemistry, 2014, 289, 5510-5517.	1.6	102
546	Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. Diabetes, 2014, 63, 312-322.	0.3	58
547	Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis , , ,. American Journal of Clinical Nutrition, 2014, 100, 833-849.	2.2	204
548	Dietary patterns associated with magnetic resonance imaging–determined liver fat content in a general population study. American Journal of Clinical Nutrition, 2014, 99, 369-377.	2.2	45
549	Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. European Journal of Surgical Oncology, 2014, 40, 1436-1444.	0.5	17
550	Whole body magnetic resonance imaging (MRI). , 2014, , 266-306.		0
551	Latest developments in the imaging of fibrotic liver disease. Acta Radiologica, 2014, 55, 802-813.	0.5	6
552	Editorial: Noninvasive Prediction of Hepatic Steatosis. American Journal of Gastroenterology, 2014, 109, 1415-1416.	0.2	2
553	Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 397-416.	0.6	15
554	Hepatic Steatosis in Living Liver Donor Candidates: Preoperative Assessment by Using Breath-hold Triple-Echo MR Imaging and ¹ H MR Spectroscopy. Radiology, 2014, 271, 730-738.	3.6	50
555	Effects of dietary interventions on liver volume in humans. Obesity, 2014, 22, 989-995.	1.5	34
556	Quantitative Determination of Liver Triglyceride Levels with 3T 1H-MR Spectroscopy in Mice with Moderately Elevated Liver Fat Content. Academic Radiology, 2014, 21, 1446-1454.	1.3	7

#	Article	IF	CITATIONS
557	Adiposity and hepatic lipid in healthy full-term, breastfed, and formula-fed human infants: a prospective short-term longitudinal cohort study. American Journal of Clinical Nutrition, 2014, 99, 1034-1040.	2.2	15
558	Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery. Surgery Today, 2014, 44, 1611-1625.	0.7	64
559	Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors. Digestive Diseases and Sciences, 2014, 59, 2571-2579.	1.1	74
560	Liver fat accumulation is associated with reduced hepatic insulin extraction and beta cell dysfunction in healthy older individuals. Diabetology and Metabolic Syndrome, 2014, 6, 43.	1.2	28
561	Quantification of liver iron with MRI: State of the art and remaining challenges. Journal of Magnetic Resonance Imaging, 2014, 40, 1003-1021.	1.9	208
562	Increasing Protein Intake Modulates Lipid Metabolism in Healthy Young Men and Women Consuming a High-Fat Hypercaloric Diet. Journal of Nutrition, 2014, 144, 1174-1180.	1.3	29
563	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European Journal of Clinical Nutrition, 2014, 68, 416-423.	1.3	255
564	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes and Endocrinology,the, 2014, 2, 901-910.	5.5	938
565	Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. Journal of Magnetic Resonance Imaging, 2014, 39, 1494-1501.	1.9	78
566	Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America, 2014, 98, 55-72.	1.1	31
567	Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 406-416.	5.5	98
568	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. Journal of Hepatology, 2014, 60, 809-815.	1.8	34
569	Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1155-1161.	1.1	124
570	Predicting Hepatic Steatosis in a Racially and Ethnically Diverse Cohort of Adolescent Girls. Journal of Pediatrics, 2014, 165, 319-325.e1.	0.9	30
571	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2121-2130.e2.	2.4	97
572	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 475.	1.4	453
573	Section 1. Image Evaluation of Fatty Liver in Living Donor Liver Transplantation. Transplantation, 2014, 97, S3-S6.	0.5	15
574	In vivo relaxation behavior of liver compounds at 7 tesla, measured by singleâ€voxel proton MR	1.9	19

#	Article	IF	Citations
575	Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. British Journal of Nutrition, 2015, 114, 780-787.	1.2	13
576	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1484-E1490.	1.8	6
577	Imaging methods for analyzing body composition in human obesity and cardiometabolic disease. Annals of the New York Academy of Sciences, 2015, 1353, 41-59.	1.8	67
578	Acute exercise does not decrease liver fat in men with overweight or NAFLD. Scientific Reports, 2015, 5, 9709.	1.6	30
579	Metabolically normal obese people are protected from adverse effects following weight gain. Journal of Clinical Investigation, 2015, 125, 787-795.	3.9	132
581	Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. Diabetes/Metabolism Research and Reviews, 2015, 31, 734-744.	1.7	37
582	Phagocytic function of Kupffer cells in mouse nonalcoholic fatty liver disease models: Evaluation with superparamagnetic iron oxide. Journal of Magnetic Resonance Imaging, 2015, 41, 1218-1227.	1.9	17
583	Quantification of liver fat with respiratoryâ€gated quantitative chemical shift encoded MRI. Journal of Magnetic Resonance Imaging, 2015, 42, 1241-1248.	1.9	24
584	A clinically relevant method to screen for hepatic steatosis in overweight adolescents: a cross sectional study. BMC Pediatrics, 2015, 15, 151.	0.7	14
585	Effects of low-stearate palm oil and high-stearate lard high-fat diets on rat liver lipid metabolism and glucose tolerance. Nutrition and Metabolism, 2015, 12, 57.	1.3	11
586	Ultrashort-TE stimulated echo acquisition mode (STEAM) improves the quantification of lipids and fatty acid chain unsaturation in the human liver at 7 T. NMR in Biomedicine, 2015, 28, 1283-1293.	1.6	27
587	Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases. Obesity, 2015, 23, 1929-1937.	1.5	25
588	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver International, 2015, 35, 2139-2146.	1.9	169
589	TypeÂ1 diabetes is not associated with an increased prevalence of hepatic steatosis. Diabetic Medicine, 2015, 32, 1648-1651.	1.2	36
590	Fifty Years of Technological Innovation. Investigative Radiology, 2015, 50, 584-593.	3.5	24
591	I148 <scp>M</scp> variant in <i><scp>PNPLA</scp>3</i> reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver International, 2015, 35, 2537-2546.	1.9	27
592	Reproducibility of MRâ€based liver fat quantification across field strength: Sameâ€day comparison between 1.5T and 3T in obese subjects. Journal of Magnetic Resonance Imaging, 2015, 42, 811-817.	1.9	67
593	In vivo breathâ€hold ¹ H MRS simultaneous estimation of liver proton density fat fraction, and <i>T</i> ₁ and <i>T</i> ₂ of water and fat, with a multiâ€TR, multiâ€TE sequence. Journal of Magnetic Resonance Imaging, 2015, 42, 1538-1543.	1.9	32

#	Article	IF	CITATIONS
594	<i>In vivo</i> ¹ H MRS and ³¹ P MRSI of the response to cyclocreatine in transgenic mouse liver expressing creatine kinase. NMR in Biomedicine, 2015, 28, 1634-1644.	1.6	1
595	Quantitative susceptibility mapping in the abdomen as an imaging biomarker of hepatic iron overload. Magnetic Resonance in Medicine, 2015, 74, 673-683.	1.9	98
596	Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Medicine (United States), 2015, 94, e1103.	0.4	7
598	State-of-the-art cross-sectional liver imaging: beyond lesion detection and characterization. Journal of Hepatocellular Carcinoma, 2015, 2, 101.	1.8	6
599	Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients, 2015, 7, 4995-5019.	1.7	142
600	LPSF/GQ-02 Inhibits the Development of Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD). PLoS ONE, 2015, 10, e0123787.	1.1	13
601	Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2015, 10, e0134172.	1.1	163
602	Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients. PLoS ONE, 2015, 10, e0125653.	1.1	35
603	Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR Imaging. PLoS ONE, 2015, 10, e0141691.	1.1	15
604	In Nonobese Girls, Waist Circumference as a Predictor of Insulin Resistance Is Comparable to MRI Fat Measures and Superior to BMI. Hormone Research in Paediatrics, 2015, 84, 258-265.	0.8	9
605	Dietary Patterns Associated with Magnetic Resonance Imaging–determined Liver Fat Content in a German General Population Study International Journal of Epidemiology, 2015, 44, i7-i7.	0.9	0
606	Hepatic Steatosis Is Prevalent in Stillborns Delivered to Women With Diabetes Mellitus. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 152-158.	0.9	55
607	Quantitative relationship between liver fat content and metabolic syndrome in obese children and adolescents. Clinical Endocrinology, 2015, 83, 43-49.	1.2	11
608	Hepatic fat quantification using the proton density fat fraction (PDFF): utility of free-drawn-PDFF with a large coverage area. Radiologia Medica, 2015, 120, 1083-1093.	4.7	23
609	Improved Method for Calculating Hepatic Steatosis Using the Hepatorenal Index. Journal of Ultrasound in Medicine, 2015, 34, 1051-1059.	0.8	38
610	Influence of Plasma Cortisol and Other Laboratory Parameters on Nonalcoholic Fatty Liver Disease. Hormone and Metabolic Research, 2015, 47, 479-484.	0.7	12
611	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1039-1053.	1.4	13
612	Dyslipidemia: Relationship to Insulin Resistance, Fatty Liver, and Sub-Clinical Atherosclerosis. , 2015, , 65-79.		0

#	Article	IF	CITATIONS
613	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2231-2238.	1.8	404
614	Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXR <i>α</i> Activity and a Favorable Window in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 305-314.	1.3	30
615	Ultrasound-based tissue characterization and classification of fatty liver disease: A screening and diagnostic paradigm. Knowledge-Based Systems, 2015, 75, 66-77.	4.0	62
616	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. Journal of Hepatology, 2015, 62, 405-411.	1.8	98
617	Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology, 2015, 61, 1887-1895.	3.6	138
618	Consumption of a whey protein-enriched diet may prevent hepatic steatosis associated with weight gain in elderly women. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 388-395.	1.1	12
619	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. American Journal of Gastroenterology, 2015, 110, 1306-1314.	0.2	240
620	In vivo proton magnetic resonance spectroscopy of liver metabolites in non-alcoholic fatty liver disease in rats: T2 relaxation times in methylene protons. Chemistry and Physics of Lipids, 2015, 191, 1-7.	1.5	7
621	The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology, 2015, 5, 147-158.	0.4	114
622	Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: A cross-sectional study. Metabolism: Clinical and Experimental, 2015, 64, 1077-1085.	1.5	28
623	Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. European Journal of Radiology, 2015, 84, 1452-1458.	1.2	23
625	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms. Current Diabetes Reports, 2015, 15, 607.	1.7	102
626	NAFLD: A multisystem disease. Journal of Hepatology, 2015, 62, S47-S64.	1.8	2,037
627	Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. Abdominal Imaging, 2015, 40, 1512-1519.	2.0	78
628	Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. American Journal of Clinical Nutrition, 2015, 101, 65-71.	2.2	47
629	Normal weight individuals who develop TypeÂ2 diabetes: the personal fat threshold. Clinical Science, 2015, 128, 405-410.	1.8	121
631	Dietary patterns and fatty liver disease. Current Opinion in Lipidology, 2015, 26, 35-41.	1.2	14
632	Translational Imaging Research. , 2015, , 189-194.		2

#	Article	IF	CITATIONS
633	Fibrosis stage is the strongest predictor for diseaseâ€specific mortality in NAFLD after up to 33 years of followâ€up. Hepatology, 2015, 61, 1547-1554.	3.6	1,683
634	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 222-232.e2.	2.3	209
635	A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia, 2015, 58, 2877-2884.	2.9	56
636	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs, 2015, 75, 1373-1392.	4.9	61
637	Impact of nonâ€alcoholic fatty liver disease on liver volume in humans. Hepatology Research, 2015, 45, 210-219.	1.8	16
638	Predicting hepatic steatosis and liver fat content in obese children based on biochemical parameters and anthropometry. Pediatric Obesity, 2015, 10, 112-117.	1.4	12
639	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in Liver Disease, 2015, 35, 270-290.	1.8	135
640	Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. European Radiology, 2015, 25, 2921-2930.	2.3	54
641	Nonalcoholic fatty liver disease – current status and future directions. Journal of Digestive Diseases, 2015, 16, 541-557.	0.7	80
642	Molecular mechanisms of fatty liver in obesity. Frontiers of Medicine, 2015, 9, 275-287.	1.5	24
643	Current and Future Burden of Chronic Nonmalignant LiverÂDisease. Clinical Gastroenterology and Hepatology, 2015, 13, 2031-2041.	2.4	111
644	Feasibility of and agreement between MR imaging and spectroscopic estimation of hepatic proton density fat fraction in children with known or suspected nonalcoholic fatty liver disease. Abdominal Imaging, 2015, 40, 3084-3090.	2.0	20
645	Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. European Journal of Endocrinology, 2015, 173, 739-747.	1.9	29
646	Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacologica Sinica, 2015, 36, 44-50.	2.8	138
647	Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. Journal of Hepatology, 2015, 62, 657-663.	1.8	104
648	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 2015, 64, 1744-1754.	6.1	950
649	Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. American Journal of Clinical Nutrition, 2015, 101, 34-43.	2.2	128
650	Effects of physical activity upon the liver. European Journal of Applied Physiology, 2015, 115, 1-46.	1.2	71

#	ARTICLE	IF	CITATIONS
651	Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdominal Imaging, 2015, 40, 26-37.	2.0	22
652	Measuring short-term liver metabolism non-invasively: postprandial and post-exercise 1H and 31P MR spectroscopy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2015, 28, 57-66.	1.1	7
653	Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-6.	0.8	5
654	Intrahepatic Fat Content and Markers of Hepatic Fibrosis in Obese Children. International Journal of Endocrinology, 2016, 2016, 1-10.	0.6	2
655	Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology, 2016, 22, 6318.	1.4	131
657	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterology Research and Practice, 2016, 2016, 1-17.	0.7	54
658	Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by ¹ H-Magnetic Resonance Spectroscopy. International Journal of Endocrinology, 2016, 2016, 1-6.	0.6	2
659	Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-7.	0.8	37
660	Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. Journal of Obesity, 2016, 2016, 1-10.	1.1	17
661	The Flexibility of Ectopic Lipids. International Journal of Molecular Sciences, 2016, 17, 1554.	1.8	26
662	Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 633.	1.8	114
663	Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids. International Journal of Molecular Sciences, 2016, 17, 1089.	1.8	4
664	Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. Frontiers in Pharmacology, 2016, 7, 159.	1.6	67
665	Hepatic steatosis and fibrosis: Non-invasive assessment. World Journal of Gastroenterology, 2016, 22, 9880.	1.4	62
666	Sensitivity of chemical shiftâ€encoded fat quantification to calibration of fat MR spectrum. Magnetic Resonance in Medicine, 2016, 75, 845-851.	1.9	52
667	Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity and Metabolism, 2016, 18, 882-891.	2.2	175
668	Liver function as an engineering system. AICHE Journal, 2016, 62, 3285-3297.	1.8	9
669	Quantification of renal steatosis in type II diabetes mellitus using dixonâ€based MRI. Journal of Magnetic Resonance Imaging, 2016, 44, 1312-1319.	1.9	27

#	Article	IF	CITATIONS
670	Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor â€î³ (<i><scp>PPARG</scp></i>) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (<i><scp>LMNA</scp></i>) mutations. Diabetic Medicine, 2016, 33, 1445-1450.	1.2	18
671	Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology, 2016, 9, 692-701.	1.4	123
672	Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology, 2016, 64, 1969-1977.	3.6	237
673	Choline Supplementation With a Structured Lipid in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 618-626.	0.9	21
675	Are hepatic and soleus lipid content, assessed by magnetic resonance spectroscopy, associated with low birth weight or insulin resistance in a rural Indian population of healthy young men?. Diabetic Medicine, 2016, 33, 365-370.	1.2	4
676	Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 24031.	1.6	15
677	How to Perform Selective Liver Biopsy in Living Liver Donors Using Plain Computed Tomography. Transplantation, 2016, 100, 2398-2403.	0.5	3
678	Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Scientific Reports, 2016, 6, 24740.	1.6	21
681	Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open, 2016, 6, e010342.	0.8	30
682	Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. Journal of Biological Chemistry, 2016, 291, 10659-10676.	1.6	172
683	Plasma apolipoprotein C1 concentration is associated with plasma triglyceride concentration, but not visceral fat, in patients with type 2 diabetes. Diabetes and Metabolism, 2016, 42, 263-266.	1.4	14
684	Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging. Abdominal Radiology, 2016, 41, 1744-1750.	1.0	2
685	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 451-496.	9.6	449
686	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Digestive Diseases and Sciences, 2016, 61, 1214-1225.	1.1	130
687	The effect of water suppression on the hepatic lipid quantification, as assessed by the LCModel, in a preclinical and clinical scenario. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 29-37.	1.1	2
688	Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. Journal of Investigative Medicine, 2016, 64, 63-68.	0.7	26
689	Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia, 2016, 59, 1104-1111.	2.9	76
690	Hypoxia-inducible factors as molecular targets for liver diseases. Journal of Molecular Medicine, 2016, 94, 613-627.	1.7	104

#	Article	IF	CITATIONS
691	Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease. Journal of Applied Physiology, 2016, 120, 1159-1164.	1.2	19
692	Impact of anthropometric cutâ€off values in determining the prevalence of metabolic alterations. European Journal of Clinical Investigation, 2016, 46, 940-946.	1.7	11
693	Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease. Clinical Science, 2016, 130, 93-104.	1.8	100
694	Proposed cut-off value of the intrahepatic lipid content for metabolically normal persons assessed by proton magnetic resonance spectroscopy in a Japanese population. Diabetes Research and Clinical Practice, 2016, 119, 75-82.	1.1	5
695	Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2775.	1.8	142
696	KBH-1, an herbal composition, improves hepatic steatosis and leptin resistance in high-fat diet-induced obese rats. BMC Complementary and Alternative Medicine, 2016, 16, 355.	3.7	14
697	Additive effects of dexamethasone and palmitate on hepatic lipid accumulation and secretion. Journal of Molecular Endocrinology, 2016, 57, 261-273.	1.1	10
698	Genetic Variation in the 11β-hydroxysteroid-dehydrogenase 1 Gene Determines NAFLD and Visceral Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4743-4751.	1.8	20
699	Obesity, NASH, and HCC. , 2016, , 275-286.		0
700	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156.	2.7	61
700	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200.	2.7 2.1	61 5
700 701 702	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510.	2.7 2.1 0.7	61 5 73
700 701 702 703	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510. Tree shrew (<i>Tupaia belangeri chinensis</i>), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 2016, 5, 1545-1552.	2.7 2.1 0.7 0.6	61 5 73 17
700 701 702 703	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510. Tree shrew (<i>Tupaia belangeri chinensis</i>), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 2016, 5, 1545-1552. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease. Pediatrics, 2016, 138,.	2.7 2.1 0.7 0.6 1.0	61 5 73 17 23
 700 701 702 703 704 705 	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510. Tree shrew (<i>Tupaia belangeri chinensis</i>), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 2016, 5, 1545-1552. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease. Pediatrics, 2016, 138,. Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. Journal of Computer Assisted Tomography, 2016, 40, 678-682.	2.7 2.1 0.7 0.6 1.0	 61 5 73 17 23 4
 700 701 702 703 704 705 706 	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510. Tree shrew (<i>Tupaia belangeri chinensis</i>), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 2016, 5, 1545-1552. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease. Pediatrics, 2016, 138, . Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. Journal of Computer Assisted Tomography, 2016, 40, 678-682. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease. Journal of Digestive Diseases, 2016, 17, 565-571.	2.7 2.1 0.7 0.6 1.0 0.5	 61 5 73 17 23 4 11
 700 701 702 703 704 705 706 707 	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156. Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics, 2016, 72, 195-200. Hepatic Steatosis: Etiology, Patterns, and Quantification. Seminars in Ultrasound, CT and MRI, 2016, 37, 501-510. Tree shrew (<1>Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 2016, 5, 1545-1552. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease. Pediatrics, 2016, 138. Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. Journal of Computer Assisted Tomography, 2016, 40, 678-682. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease. Journal of Digestive Diseases, 2016, 17, 565-571. Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans. Scientific Reports, 2016, 6, 26745.	 2.7 2.1 0.7 0.6 1.0 0.5 0.7 1.6 	 61 5 73 17 23 4 11 224

#	Article	IF	CITATIONS
709	Resolution of nonâ€alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism. Pediatric Transplantation, 2016, 20, 1157-1163.	0.5	15
710	Effects of aerobic exercise on ectopic lipids in patients with growth hormone deficiency before and after growth hormone replacement therapy. Scientific Reports, 2016, 6, 19310.	1.6	8
711	Transwomen and the Metabolic Syndrome: Is Orchiectomy Protective?. Transgender Health, 2016, 1, 165-171.	1.2	16
712	Thiazolidinediones for nonalcoholic steatohepatitis. Medicine (United States), 2016, 95, e4947.	0.4	43
713	MRIâ€determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes. Journal of Magnetic Resonance Imaging, 2016, 43, 1090-1099.	1.9	41
714	Liver Stiffness Measurements with MR Elastography: Agreement and Repeatability across Imaging Systems, Field Strengths, and Pulse Sequences. Radiology, 2016, 281, 793-804.	3.6	105
715	Ectopic and Visceral Fat Deposition inÂLean and Obese Patients With TypeÂ2ÂDiabetes. Journal of the American College of Cardiology, 2016, 68, 53-63.	1.2	165
716	Association between Hepatic Triglyceride Content and Left Ventricular Diastolic Function in a Population-based Cohort: The Netherlands Epidemiology of Obesity Study. Radiology, 2016, 279, 443-450.	3.6	15
717	Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. International Journal of Obesity, 2016, 40, 747-753.	1.6	43
718	Alcoholic and Non-Alcoholic Fatty Liver Disease. , 2016, , .		5
719	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 277-292.	1.0	32
720	Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1728-1744.e7.	0.6	202
721	Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1637-1646.	1.8	26
722	A Diet Rich in Medium-Chain Fatty Acids Improves Systolic Function and Alters the Lipidomic Profile in Patients With Type 2 Diabetes: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 504-512.	1.8	39
723	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 644-652.	1.8	127
724	Diagnostic Considerations and Clinical End Points for Nonalcoholic Steatohepatitis. , 2016, , 211-221.		0
725	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1798-1806.	1.8	40
726	Quantification of liver fat: A comprehensive review. Computers in Biology and Medicine, 2016, 71, 174-189.	3.9	58

#	Article	IF	CITATIONS
727	The Association of Alanine Aminotransferase in Early Pregnancy with Gestational Diabetes. Metabolic Syndrome and Related Disorders, 2016, 14, 254-258.	0.5	18
728	Quantitative Ultrasound for Staging of Hepatic Steatosis in Patients on Home Parenteral Nutrition Validated with Magnetic Resonance Spectroscopy: A Feasibility Study. Ultrasound in Medicine and Biology, 2016, 42, 637-644.	0.7	13
729	Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H14-H19.	1.5	62
730	Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. Surgery, 2016, 159, 1050-1057.	1.0	14
731	High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia, 2016, 59, 56-66.	2.9	141
732	Hepatic Steatosis: Assessment with Acoustic Structure Quantification of US Imaging. Radiology, 2016, 278, 257-264.	3.6	60
733	Accelerating MR Imaging Liver Steatosis Measurement Using Combined Compressed Sensing and Parallel Imaging: A Quantitative Evaluation. Radiology, 2016, 278, 247-256.	3.6	32
734	GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetologica, 2016, 53, 237-242.	1.2	17
735	A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiologica, 2016, 57, 271-278.	0.5	123
736	Race/ethnic and sex disparities in the non-alcoholic fatty liver disease-abdominal aortic calcification association: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2017, 258, 89-96.	0.4	17
737	Red paprika (Capsicum annuum L.) and its main carotenoid capsanthin ameliorate impaired lipid metabolism in the liver and adipose tissue of high-fat diet-induced obese mice. Journal of Functional Foods, 2017, 31, 131-140.	1.6	35
738	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology, 2017, 65, 1088-1090.	3.6	20
739	An extended fatty liver index to predict non-alcoholic fatty liver disease. Diabetes and Metabolism, 2017, 43, 229-239.	1.4	22
740	Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clinical Endocrinology, 2017, 86, 698-707.	1.2	72
741	Proton Density Fat Fraction Measurements at 1.5- and 3-T Hepatic MR Imaging: Same-Day Agreement among Readers and across Two Imager Manufacturers. Radiology, 2017, 284, 244-254.	3.6	66
742	What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver. Gut, 2017, 66, 1732-1733.	6.1	1
743	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology, 2017, 153, 53-55.e7.	0.6	51
744	Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alphaâ€inhibitory dithiolethione in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1073-1083.	1.9	56

#	Article	IF	CITATIONS
745	Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. Scientific Reports, 2017, 7, 40977.	1.6	14
746	Risk of Obesity-Related Cardiometabolic Complications in Special Populations: A Crisis in Asians. Gastroenterology, 2017, 152, 1647-1655.	0.6	21
747	Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nature Genetics, 2017, 49, 842-847.	9.4	288
748	Nonâ€alcoholic fatty liver disease (<scp>NAFLD</scp>) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1630-1634.	2.2	137
749	Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with nonâ€elcoholic fatty liver disease: A pilot randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1814-1817.	2.2	71
750	Circulating selenoprotein P levels in relation to MRIâ€derived body fat volumes, liver fat content, and metabolic disorders. Obesity, 2017, 25, 1128-1135.	1.5	19
751	Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. Radiology, 2017, 284, 706-716.	3.6	91
752	1 H MRS Assessment of Hepatic Fat Content. Academic Radiology, 2017, 24, 982-987.	1.3	13
753	Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (United States), 2017, 96, e6770.	0.4	41
754	Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clinical Science, 2017, 131, 1905-1917.	1.8	38
755	<scp>NAFLD</scp> in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by ¹ Hâ€ <scp>MRS</scp> ?. Liver International, 2017, 37, 1907-1915.	1.9	16
756	Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. Cell Reports, 2017, 19, 1997-2004.	2.9	117
757	Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. European Journal of Gastroenterology and Hepatology, 2017, 29, 481-487.	0.8	37
758	Is Hepatic Triglyceride Content Associated with Aortic Pulse Wave Velocity and Carotid Intima-Media Thickness? The Netherlands Epidemiology of Obesity Study. Radiology, 2017, 285, 73-82.	3.6	3
759	Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. Journal of Nutritional Science, 2017, 6, e15.	0.7	10
760	Waist circumference is associated with liver fat in black and white adolescents. Applied Physiology, Nutrition and Metabolism, 2017, 42, 829-833.	0.9	15
761	Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample. European Journal of Clinical Nutrition, 2017, 71, 995-1001.	1.3	20
762	Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. International Journal of Obesity, 2017, 41, 262-267.	1.6	24

#	Article	IF	Citations
763	Glucocorticoid Regulation of Body Composition and Metabolism. , 2017, , 3-26.		3
764	Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism: Clinical and Experimental, 2017, 69, 1-13.	1.5	165
765	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology, 2017, 65, 1132-1144.	3.6	191
766	Fatty Pancreas. Pancreas, 2017, 46, 1251-1258.	0.5	60
767	Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study. Diabetologia, 2017, 60, 2341-2351.	2.9	24
768	Quantitative Imaging in Diffuse Liver Diseases. Seminars in Liver Disease, 2017, 37, 243-258.	1.8	11
769	The effect of diet or exercise on ectopic adiposity in children and adolescents with obesity: a systematic review and metaâ€analysis. Obesity Reviews, 2017, 18, 1310-1322.	3.1	17
770	Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets. Clinical Science, 2017, 131, 2561-2573.	1.8	31
771	Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterology, 2017, 4, e000139.	1.1	95
772	Impact of pioglitazone on bone mineral density and bone marrow fat content. Osteoporosis International, 2017, 28, 3261-3269.	1.3	25
773	The effects of concomitant gradients on chemical shift encoded MRI. Magnetic Resonance in Medicine, 2017, 78, 730-738.	1.9	22
774	The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Scientific Reports, 2017, 7, 2261.	1.6	20
775	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case–control study. European Journal of Gastroenterology and Hepatology, 2017, 29, 309-316.	0.8	11
776	Serum ferritin as a nonâ€invasive marker in the prediction of hepatic fibrosis among Egyptian patients with nonâ€alcoholic fatty liver disease. JGH Open, 2017, 1, 112-119.	0.7	13
777	Fat Quantification in the Abdomen. Topics in Magnetic Resonance Imaging, 2017, 26, 221-227.	0.7	22
778	Added fructose as a principal driver of non-alcoholic fatty liver disease: a public health crisis. Open Heart, 2017, 4, e000631.	0.9	21
779	Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) – an 11-Year Prospective Study. Scientific Reports, 2017, 7, 14561.	1.6	18
780	The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. Molecular Metabolism, 2017, 6, 1493-1502.	3.0	23

#	Article	IF	CITATIONS
781	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia, 2017, 60, 1873-1882.	2.9	85
782	Standardized Approach for ROI-Based Measurements of Proton Density Fat Fraction and R2* in the Liver. American Journal of Roentgenology, 2017, 209, 592-603.	1.0	68
783	Significance of nonâ€alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study. Hepatology Research, 2017, 47, 872-881.	1.8	22
784	Nonalcoholic Steatohepatitis. Annual Review of Medicine, 2017, 68, 85-98.	5.0	119
785	Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Gastroenterology, 2017, 152, 571-585.e8.	0.6	194
786	Non-invasive diagnosis of hepatic steatosis. Hepatology International, 2017, 11, 70-78.	1.9	101
787	Liver triacylglycerol content and gestational diabetes: effects of moderate energy restriction. Diabetologia, 2017, 60, 306-313.	2.9	12
788	Quantification of liver fat in the presence of iron overload. Journal of Magnetic Resonance Imaging, 2017, 45, 428-439.	1.9	39
789	Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrastâ€Enhanced MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 1485-1493.	1.9	7
790	Parenteral nutrition dysregulates bile salt homeostasis in a rat model of parenteral nutrition-associated liver disease. Clinical Nutrition, 2017, 36, 1403-1410.	2.3	12
791	Accuracy of Liver Fat Quantification With Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR Spectroscopy. American Journal of Roentgenology, 2017, 208, 92-100.	1.0	180
792	Correction of phase errors in quantitative water–fat imaging using a monopolar timeâ€interleaved multiâ€echo gradient echo sequence. Magnetic Resonance in Medicine, 2017, 78, 984-996.	1.9	50
793	Noninvasive Quantitative Assessment of Hepatic Steatosis by Proton Magnetic Resonance Spectroscopy Among Adult Patients Receiving Home Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2017, 42, 014860711771166.	1.3	7
794	Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. Journal of the Endocrine Society, 2017, 1, 1417-1427.	0.1	22
795	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. Current Hepatology Reports, 2017, 16, 298-307.	0.4	9
796	Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. Thrombosis and Haemostasis, 2017, 117, 286-294.	1.8	18
797	Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients, 2017, 9, 981.	1.7	226
798	Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content. Nutrients, 2017, 9, 1143.	1.7	33

#	Article	IF	CITATIONS
799	Pancreatic size and fat content in diabetes: A systematic review and meta-analysis of imaging studies. PLoS ONE, 2017, 12, e0180911.	1.1	50
800	Natural History of NAFLD/NASH. Current Hepatology Reports, 2017, 16, 391-397.	0.4	102
801	Effect of Gadoxetic Acid on Quantification of Hepatic Steatosis Using Magnetic Resonance Spectroscopy: A Prospective Study. Journal of the Korean Society of Radiology, 2017, 76, 237.	0.1	0
802	Radiologic Evaluation of Non-Alcoholic Fatty Liver Disease in Diabetic Patient. Journal of Korean Diabetes, 2017, 18, 88.	0.1	1
803	Comparative Study of Ultrasonography, Computed Tomography, Magnetic Resonance Imaging, and Magnetic Resonance Spectroscopy for the Diagnosis of Fatty Liver in a Rat Model. Journal of the Korean Society of Radiology, 2017, 76, 14.	0.1	5
804	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8263-8276.	1.4	514
805	High SNR Acquisitions Improve the Repeatability of Liver Fat Quantification Using Confounder-corrected Chemical Shift-encoded MR Imaging. Magnetic Resonance in Medical Sciences, 2017, 16, 332-339.	1.1	11
806	Quantitative analysis of hepatic iron in patients suspected of coexisting iron overload and steatosis using multiâ€echo singleâ€voxel magnetic resonance spectroscopy: Comparison with fatâ€saturated multiâ€echo gradient echo sequence. Journal of Magnetic Resonance Imaging, 2018, 48, 205-213.	1.9	16
807	Improved quantitative fatty acid values with correction of T2 relaxation time in terminal methyl group: In vivo proton magnetic resonance spectroscopy at ultra high field in hepatic steatosis. Chemistry and Physics of Lipids, 2018, 212, 35-43.	1.5	2
808	Validation of a motionâ€robust 2D sequential technique for quantification of hepatic proton density fat fraction during free breathing. Journal of Magnetic Resonance Imaging, 2018, 48, 1578-1585.	1.9	16
810	Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. Advances in Nutrition, 2018, 9, 30-40.	2.9	68
811	Estimation of hepatic fat fraction using modified Dixon magnetic resonance imaging techniques: effect of liver cirrhosis. Clinical Imaging, 2018, 51, 50-58.	0.8	6
812	Evidence-Based Exercise Recommendations to Reduce Hepatic Fat Content in Youth- a Systematic Review and Meta-Analysis. Progress in Cardiovascular Diseases, 2018, 61, 222-231.	1.6	34
813	Estimation of proton density fat fraction of the salivary gland. British Journal of Radiology, 2018, 91, 20170671.	1.0	7
814	Noise properties of proton density fat fraction estimated using chemical shift–encoded MRI. Magnetic Resonance in Medicine, 2018, 80, 685-695.	1.9	17
815	Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nature Communications, 2018, 9, 272.	5.8	119
816	Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology, 2018, 67, 2182-2195.	3.6	51
817	Angiopoietinâ€like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in nonâ€alcoholic fatty liver disease patients. Journal of Diabetes Investigation, 2018, 9, 952-958.	1.1	22

#	ARTICLE European Association for the Study of the Liver (<scp>EASL</scp>), European Association for the	IF	CITATIONS
818	Study of Diabetes (<scp>EASD</scp>) and European Association for the Study of Obesity (<scp>EASO</scp>) clinical practice recommendations for the management of nonâ€alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabetic Medicine, 2018, 35, 368-375.	1.2	101
819	Epidemiology of Hepatic Steatosis at a Tertiary Care Center. Academic Radiology, 2018, 25, 317-327.	1.3	9
820	Feasibility of balanced steady-state free precession sequence at 1.5T for the evaluation of hepatic steatosis in obese children and adolescents. European Radiology, 2018, 28, 4479-4487.	2.3	2
821	Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. Ultrasound in Medicine and Biology, 2018, 44, 1585-1596.	0.7	16
822	Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1130-1138.	1.8	28
823	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Molecular Aspects of Medicine, 2018, 64, 135-146.	2.7	103
824	Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. Atherosclerosis, 2018, 272, 47-53.	0.4	10
825	Freeâ€breathing liver fat quantification using a multiecho 3 <scp>D</scp> stackâ€ofâ€radial technique. Magnetic Resonance in Medicine, 2018, 79, 370-382.	1.9	40
826	Multiple breathâ€hold proton spectroscopy of human liver at 3T: Relaxation times and concentrations of glycogen, choline, and lipids. Journal of Magnetic Resonance Imaging, 2018, 47, 410-417.	1.9	17
827	Validation of intimate correlation between visceral fat and hepatic steatosis: Quantitative measurement techniques using CT for area ofÂfat and MR for hepatic steatosis. Clinical Nutrition, 2018, 37, 214-222.	2.3	13
828	Effects of a diet rich in arabinoxylan and resistant starch compared with a diet rich in refined carbohydrates on postprandial metabolism and features of the metabolic syndrome. European Journal of Nutrition, 2018, 57, 795-807.	1.8	19
829	Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. Clinical Nutrition, 2018, 37, 1752-1758.	2.3	30
830	Adipose tissue and liver. Journal of Applied Physiology, 2018, 124, 162-167.	1.2	12
831	Lipid droplet proteins and metabolic diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1968-1983.	1.8	123
832	Preperitoneal fat as a nonâ€invasive marker of increased risk of severe nonâ€alcoholic fatty liver disease in patients with type 2 diabetes. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 511-517.	1.4	18
833	Asia–Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 70-85.	1.4	358
834	Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels. Hormone and Metabolic Research, 2018, 50, 303-307.	0.7	4
835	Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity — A randomized trial. Metabolism: Clinical and Experimental, 2018, 78, 128-140.	1.5	94

#	Article	IF	CITATIONS
836	Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice. Metabolic Brain Disease, 2018, 33, 63-77.	1.4	11
837	Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. Journal of Nutritional Biochemistry, 2018, 52, 92-102.	1.9	41
838	MR Spectroscopy–derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. Radiology, 2018, 286, 547-556.	3.6	79
839	Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology, 2018, 286, 486-498.	3.6	225
840	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. Journal of Investigative Medicine, 2018, 66, 661-668.	0.7	3
841	Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 313-318.	1.3	5
842	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology, 2018, 68, 353-361.	1.8	58
843	Bariatric Surgery–Induced Cardiac and Lipidomic Changes in Obesityâ€Related Heart Failure with Preserved Ejection Fraction. Obesity, 2018, 26, 284-290.	1.5	68
844	Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. Journal of Hepatology, 2018, 68, 296-304.	1.8	92
845	The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E266-E273.	1.8	56
846	Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E165-E173.	1.8	46
847	Diffuse Liver Diseases: Role of imaging. Seminars in Ultrasound, CT and MRI, 2018, 39, 193-205.	0.7	5
848	Improvement of a combined ultrasonic probe used in ultrasonic velocity-change method for evaluation of fat content. Japanese Journal of Applied Physics, 2018, 57, 07LF18.	0.8	5
849	Body mass index and its effects on liver fat content in overweight and obese young adults by proton magnetic resonance spectroscopy technique. World Journal of Hepatology, 2018, 10, 924-933.	0.8	19
850	Repeatability of two-dimensional chemical shift imaging multivoxel proton magnetic resonance spectroscopy for measuring human cerebral choline-containing compounds. World Journal of Psychiatry, 2018, 8, 20-26.	1.3	1
851	Genetic variation in TCF7L2 rs7903146 and history of GDM negatively and independently impact on diabetes-associated metabolic traits. Diabetes Research and Clinical Practice, 2018, 146, 251-257.	1.1	11
852	Measurement of liver iron by magnetic resonance imaging in the UK Biobank population. PLoS ONE, 2018, 13, e0209340.	1.1	37
853	IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron. Cancer Imaging, 2018, 18, 51.	1.2	36

#	Article	IF	CITATIONS
854	A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. American Journal of Clinical Nutrition, 2018, 108, 1264-1274.	2.2	50
855	You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. American Journal of Clinical Nutrition, 2018, 108, 1162-1163.	2.2	0
856	Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS ONE, 2018, 13, e0207923.	1.1	17
857	Acute Endothelial Benefits of Fat Restriction over Carbohydrate Restriction in Type 2 Diabetes Mellitus: Beyond Carbs and Fats. Nutrients, 2018, 10, 1859.	1.7	9
858	Pancreatic fat deposition is increased and related to beta-cell function in women with familial partial lipodystrophy. Diabetology and Metabolic Syndrome, 2018, 10, 71.	1.2	9
859	Methylation of imprinted <i>IGF2</i> regions is associated with total, visceral, and hepatic adiposity in postmenopausal women. Epigenetics, 2018, 13, 858-865.	1.3	6
860	Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation. Journal of the Endocrine Society, 2018, 2, 1147-1157.	0.1	8
861	Developmental Exposure to 2,2′,4,4′-Tetrabromodiphenyl Ether Permanently Alters Blood-Liver Balance of Lipids in Male Mice. Frontiers in Endocrinology, 2018, 9, 548.	1.5	32
862	Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism. Trends in Molecular Medicine, 2018, 24, 1021-1035.	3.5	34
863	Magnetic Resonance Elastography of Liver. Topics in Magnetic Resonance Imaging, 2018, 27, 319-333.	0.7	92
864	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis, 2018, 278, 82-90.	0.4	27
865	Non-invasive quantification of hepatic fat content in healthy dogs by using proton magnetic resonance spectroscopy and dual gradient echo magnetic resonance imaging. Journal of Veterinary Science, 2018, 19, 570.	0.5	2
866	Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study. Diabetologia, 2018, 61, 2570-2579.	2.9	67
867	NAFLD and cardiovascular disease. Porto Biomedical Journal, 2018, 3, e2.	0.4	7
868	High Irisin levels in nondiabetic <scp>HIV</scp> â€infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis. Clinical Endocrinology, 2018, 89, 414-423.	1.2	18
869	Interorgan Metabolic Crosstalk in Human Insulin Resistance. Physiological Reviews, 2018, 98, 1371-1415.	13.1	138
870	Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatology Communications, 2018, 2, 786-797.	2.0	10
871	Nonalcoholic Fatty Liver Disease in University Rugby Football Players. Frontiers in Endocrinology, 2018, 9, 341.	1.5	6

ARTICLE IF CITATIONS Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese 872 0.8 19 adults. BMC Gastroenterology, 2018, 18, 113. Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus 1.8 and NAFLD. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2698-2706. 874 Fatty Liver Disease., 2018, , 308-371. 14 Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ: British Medical 2.4 Journal, 2018, 362, k2734. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic 876 1.0 25 steatosis. British Journal of Radiology, 2018, 91, 20170587. Decreased eating frequency linked to increased visceral adipose tissue, body fat, and BMI in Hispanic college freshmen. BMC Nutrition, 2018, 4, 10. Free-breathing quantification of hepatic fat in healthy children and children with nonalcoholic fatty 878 1.1 35 liver disease using a multi-echo 3-D stack-of-radial MRI technique. Pediatric Radiology, 2018, 48, 941-953. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones, 2018, 17, 69-81. 879 37 Catalase and nonalcoholic fatty liver disease. Pflugers Archiv European Journal of Physiology, 2018, 880 1.3 48 470, 1721-1737. Hepatic fat content and bone mineral density in children with overweight/obesity. Pediatric Research, 1.1 2018, 84, 684-688. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human 882 0.3 15 models. Hormone Molecular Biology and Clinical Investigation, 2020, 41, . Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease. European 883 1.2 Journal of Radiology, 2018, 107, 7-13. MRI liver fat quantification in an oncologic population: the added value of complex chemical 884 0.8 14 shift-encoded MRI. Clinical Imaging, 2018, 52, 193-199. Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network 1.6 48 Pharmacology Study. Frontiers in Pharmacology, 2018, 9, 973. Obesity-Related Metabolic Risk in Sedentary Hispanic Adolescent Girls with Normal BMI. Children, 2018, 886 0.6 4 5, 79. Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes. 1.8 30 Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3038-3049. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with 888 1.4 375 comparative analysis. World Journal of Gastroenterology, 2018, 24, 3361-3373. Extruded sorghum (Sorghum bicolor L.) reduces metabolic risk of hepatic steatosis in obese rats consuming a high fat diet. Food Research International, 2018, 112, 48-55.

#	Article	IF	CITATIONS
891	Alcohol consumption, but not smoking is associated with higher MR-derived liver fat in an asymptomatic study population. PLoS ONE, 2018, 13, e0192448.	1.1	7
892	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutrition Reviews, 2018, 76, 581-602.	2.6	88
893	Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: Evaluation with MRI. European Radiology, 2019, 29, 849-856.	2.3	34
894	Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. Abdominal Radiology, 2019, 44, 72-84.	1.0	50
895	Adult weight change in relation to visceral fat and liver fat at middle age: The Netherlands epidemiology of obesity study. International Journal of Obesity, 2019, 43, 790-799.	1.6	11
896	Whole hepatic lipid volume quantification and color mapping by multiâ€slice and multiâ€point magnetic resonance imaging. Hepatology Research, 2019, 49, 1374-1385.	1.8	4
897	Full-Range Liver Fat Fraction Estimation in Magnitude MRI Using a Signal Shape Descriptor. Concepts in Magnetic Resonance Part A: Bridging Education and Research, 2019, 2019, 1-11.	0.2	0
898	Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1197-1204.	1.1	13
899	Associations of Plasma CD36 and Body Fat Distribution. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4016-4023.	1.8	5
900	Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Molecular Medicine Reports, 2019, 19, 4673-4684.	1.1	16
901	Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-14.	1.9	10
902	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia, 2019, 62, 2066-2078.	2.9	98
903	A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk. Journal of Nutrition, 2019, 149, 1920-1929.	1.3	59
904	Proton MR spectroscopy of human pancreas allografts. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2019, 32, 511-517.	1.1	5
905	Interleukinâ€32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance. Hepatology Communications, 2019, 3, 1205-1220.	2.0	38
906	Sarcopenia and fatty liver disease. Hepatology International, 2019, 13, 674-687.	1.9	69
907	Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6171-6181.	1.8	21
908	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expression, 2019, 19, 187-198.	0.5	23

#	Article	IF	CITATIONS
909	Dietary Fructose and the Metabolic Syndrome. Nutrients, 2019, 11, 1987.	1.7	152
910	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clinical Gastroenterology and Hepatology, 2019, 17, 2816-2818.	2.4	19
911	Patients With Aldolase B Deficiency Are Characterized by Increased Intrahepatic Triglyceride Content. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5056-5064.	1.8	30
912	Effects of aging and menopause on pancreatic fat fraction in healthy women population. Medicine (United States), 2019, 98, e14451.	0.4	10
913	The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance. Endocrine Reviews, 2019, 40, 1367-1393.	8.9	341
914	Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 157, 1448-1456.e1.	0.6	11
915	Insulin resistance and NAFLD: Relationship with intrahepatic iron and serum TNF- \hat{l}_{\pm} using 1H MR spectroscopy and MRI. Diabetes and Metabolism, 2019, 45, 473-479.	1.4	15
916	Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 7922.	1.6	6
917	Separation of water and fat signal in wholeâ€body gradient echo scans using convolutional neural networks. Magnetic Resonance in Medicine, 2019, 82, 1177-1186.	1.9	29
918	Liver Zonation in Health and Disease: Hypoxia and Hypoxia-Inducible Transcription Factors as Concert Masters. International Journal of Molecular Sciences, 2019, 20, 2347.	1.8	56
919	Non-invasive Quantitative Magnetic Resonance Imaging and Spectroscopic Biomarkers in Nonalcoholic Fatty Liver Disease and Other Cardiometabolic Diseases Associated with Ectopic Fat Deposition. , 2019, , 141-160.		0
920	Effects of short-term sprint interval and moderate-intensity continuous training on liver fat content, lipoprotein profile, and substrate uptake: a randomized trial. Journal of Applied Physiology, 2019, 126, 1756-1768.	1.2	11
921	Different acute effects of fructose and glucose administration on hepatic fat content. American Journal of Clinical Nutrition, 2019, 109, 1519-1526.	2.2	8
922	Magnitudeâ€intrinsic water–fat ambiguity can be resolved with multipeak fat modeling and a multipoint search method. Magnetic Resonance in Medicine, 2019, 82, 460-475.	1.9	18
923	Current Management Strategy of Non-Alcoholic Fatty Liver Disease. Journal of Enam Medical College, 2019, 9, 46-56.	0.1	0
924	Similar Weight Loss Induces Greater Improvements in Insulin Sensitivity and Liver Function among Individuals with NAFLD Compared to Individuals without NAFLD. Nutrients, 2019, 11, 544.	1.7	8
925	Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. Nutrients, 2019, 11, 522.	1.7	18
926	Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric non-alcoholic fatty liver disease. European Journal of Pediatrics, 2019, 178, 863-870.	1.3	43

#	Article	IF	CITATIONS
927	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3327-3336.	1.8	68
928	Clinical Implementation of a Focused MRI Protocol for Hepatic Fat and Iron Quantification. American Journal of Roentgenology, 2019, 213, 90-95.	1.0	13
929	Branched chain amino acids are associated with the heterogeneity of the area of lipid droplets in hepatocytes of patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2019, 49, 860-871.	1.8	15
930	Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents. World Journal of Gastroenterology, 2019, 25, 1513-1523.	1.4	24
931	Systematic Review: Noninvasive Assessments of Intestinal Failure–Associated Liver Disease in the Adult Population. Journal of Parenteral and Enteral Nutrition, 2019, 43, 615-626.	1.3	10
932	Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. Journal of Nutrition, 2019, 149, 649-658.	1.3	10
933	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes and Metabolism Journal, 2019, 43, 31.	1.8	109
934	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 941-949.	1.9	67
935	Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention. Scientific Reports, 2019, 9, 1303.	1.6	16
936	Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. Nutrients, 2019, 11, 475.	1.7	40
937	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. , 2019, , 373-389.		2
938	Autoregressive moving average modeling for hepatic iron quantification in the presence of fat. Journal of Magnetic Resonance Imaging, 2019, 50, 1620-1632.	1.9	9
939	Hepatic Mitochondrial Oxidative Metabolism and Lipogenesis Synergistically Adapt to Mediate Healthy Embryonic-to-Neonatal Transition in Chicken. Scientific Reports, 2019, 9, 20167.	1.6	8
940	Quantitative MRI Biomarkers of Diffuse Liver Disease. Advances in Clinical Radiology, 2019, 1, 55-69.	0.1	2
942	Feasibility of non-enhanced CT for assessing longitudinal changes in hepatic steatosis. Medicine (United States), 2019, 98, e15606.	0.4	3
943	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 393-402.	0.8	12
944	Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. Medicine and Science in Sports and Exercise, 2019, 51, 1169-1177.	0.2	40
945	Agreement and Reproducibility of Proton Density Fat Fraction Measurements Using Commercial MR Sequences Across Different Platforms. Investigative Radiology, 2019, 54, 517-523.	3.5	13

#	Article	IF	CITATIONS
946	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes and Endocrinology,the, 2019, 7, 313-324.	5.5	566
947	Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study. Radiology, 2019, 290, 682-690.	3.6	22
949	Impact of Childhood Obesity in Fatty Liver Disease. , 2019, , 47-64.		0
950	Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 429-435.	1.4	9
951	Clinical Epidemiology of Chronic Liver Diseases. , 2019, , .		2
952	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: Clinical and Experimental, 2019, 92, 82-97.	1.5	679
953	Application of Magnetic Resonance Spectroscopy in metabolic research. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 741-748.	1.8	13
954	Dietary pattern associated with selenoprotein P and MRI-derived body fat volumes, liver signal intensity, and metabolic disorders. European Journal of Nutrition, 2019, 58, 1067-1079.	1.8	11
955	Assessment of a highâ€&NR chemicalâ€shiftâ€encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the lowâ€fat range. Journal of Magnetic Resonance Imaging, 2019, 49, 229-238.	1.9	9
956	Natural Course of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Patients With Human Immunodeficiency Virus With and Without Combination Antiretroviral Therapy–associated Lipodystrophy: A 16-Year Follow-up Study. Clinical Infectious Diseases, 2020, 70, 1708-1716.	2.9	6
957	Effects of plant and animal high protein diets on immune-inflammatory biomarkers: A 6-week intervention trial. Clinical Nutrition, 2020, 39, 862-869.	2.3	28
958	Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care, 2020, 43, 298-305.	4.3	185
959	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	8.9	134
960	Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. Clinical Pharmacokinetics, 2020, 59, 475-483.	1.6	9
961	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	0.9	11
962	Rat liver epigenome programing by perinatal exposure to 2,2′,4′4′-tetrabromodiphenyl ether. Epigenomics, 2020, 12, 235-249.	1.0	13
963	Sodiumâ€glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulinâ€resistant patients without type 2 diabetes. JGH Open, 2020, 4, 433-440.	0.7	10
964	Fatty liver, cardiometabolic disease and mortality. Current Opinion in Lipidology, 2020, 31, 27-31.	1.2	14

#	Article	IF	CITATIONS
965	Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. Acta Pharmacologica Sinica, 2020, 41, 554-560.	2.8	14
966	Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity. Abdominal Radiology, 2020, 45, 661-671.	1.0	16
967	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study. BMJ Open, 2020, 10, e027630.	0.8	6
968	Highâ€protein diet more effectively reduces hepatic fat than lowâ€protein diet despite lower autophagy and FGF21 levels. Liver International, 2020, 40, 2982-2997.	1.9	42
969	Magnetic resonanceâ€based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Endocrinology, Diabetes and Metabolism, 2020, 3, e00134.	1.0	11
970	Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Frontiers in Endocrinology, 2020, 11, 597583.	1.5	42
971	Zucker Lean Rats With Hepatic Steatosis Recapitulate Asymptomatic Metabolic Syndrome and Exhibit Greater Sensitivity to Drug-Induced Liver Injury Compared With Standard Nonclinical Sprague-Dawley Rat Model. Toxicologic Pathology, 2020, 48, 994-1007.	0.9	2
972	Magnetic resonance spectroscopy and its application in colorectal cancer diagnosis and screening: A narrative review. Journal of Medical Imaging and Radiation Sciences, 2020, 51, 654-661.	0.2	1
973	Fructose-palmitate based high calorie induce steatosis in HepG2 cells via mitochondrial dysfunction: An in vitro approach. Toxicology in Vitro, 2020, 68, 104952.	1.1	10
974	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2161-2171.e5.	2.4	119
975	Association Between Hepatic Triglyceride Content and Coagulation Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3004-3014.	1.1	3
976	Working Up an Incidental Finding of Hepatic Steatosis on Imaging. Clinical Liver Disease, 2020, 16, 58-62.	1.0	3
977	Validation of MRIâ€VLFF for the nonâ€invasive measurement of steatosis in children. GastroHep, 2020, 2, 171-180.	0.3	1
978	Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting. Journal of Clinical Medicine, 2020, 9, 2851.	1.0	28
979	Advances in Imaging of Diffuse Parenchymal Liver Disease. Journal of Clinical Gastroenterology, 2020, 54, 682-695.	1.1	6
980	Effect of noise and estimator type on bias for analysis of liver proton density fat fraction. Magnetic Resonance Imaging, 2020, 74, 244-249.	1.0	0
981	Administration of Protein Hydrolysates from Anchovy (Engraulis Encrasicolus) Waste for Twelve Weeks Decreases Metabolic Dysfunction-Associated Fatty Liver Disease Severity in ApoE–/–Mice. Animals, 2020, 10, 2303.	1.0	28
982	Pearls and Pitfalls of Metabolic Liver Magnetic Resonance Imaging in the Pediatric Population. Seminars in Ultrasound, CT and MRI, 2020, 41, 451-461.	0.7	1

#	Article	IF	CITATIONS
983	Adherence to a plant-based diet in relation to adipose tissue volumes and liver fat content. American Journal of Clinical Nutrition, 2020, 112, 354-363.	2.2	24
984	Association of [1H]-MRS quantified liver fat content with glucose metabolism status. Diabetology and Metabolic Syndrome, 2020, 12, 51.	1.2	3
985	New boundaries of liver imaging: from morphology to function. European Journal of Internal Medicine, 2020, 79, 12-22.	1.0	2
986	Serum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity. Frontiers in Endocrinology, 2020, 11, 340.	1.5	22
987	Overweight and obesity status from the prenatal period to adolescence and its association with nonâ€alcoholic fatty liver disease in young adults: cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1200-1209.	1.1	10
988	Managing NAFLD in TypeÂ2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review. Advances in Therapy, 2020, 37, 1381-1406.	1.3	29
989	Metabolite cycled liver 1 H MRS on a 7 T parallel transmit system. NMR in Biomedicine, 2020, 33, e4343.	1.6	6
990	Clinical assessment for highâ€risk patients with nonâ€alcoholic fatty liver disease in primary care and diabetology practices. Alimentary Pharmacology and Therapeutics, 2020, 52, 513-526.	1.9	66
991	Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 158, 1899-1912.	0.6	157
992	Adrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess. Gland Surgery, 2020, 9, 94-104.	0.5	8
993	Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clinical Biochemistry, 2020, 77, 20-25.	0.8	26
995	Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2073-2080.e7.	2.4	29
996	The correlation between the MRI-evaluated ectopic fat accumulation and the incidence of diabetes mellitus and hypertension depends on body mass index and waist circumference ratio. PLoS ONE, 2020, 15, e0226889.	1.1	13
997	Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7347-7354.	3.3	137
998	Quantification of liver fat content in liver and primary liver lesions using triple-echo-gradient-echo MRI. European Radiology, 2020, 30, 4752-4761.	2.3	3
999	A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. BioMed Research International, 2020, 2020, 1-19.	0.9	2
1000	Other types of diffuse liver disease: is there a way to do it?. Abdominal Radiology, 2020, 45, 3425-3443.	1.0	1
1001	Prevalence and risk factors of fatty liver in Portuguese adults. European Journal of Clinical Investigation, 2020, 50, e13235.	1.7	7

#	Article	IF	CITATIONS
1003	21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient. JACC: Cardiovascular Imaging, 2021, 14, 482-494.	2.3	25
1004	Unbiased approach for the identification of molecular mechanisms sensitive to chemical exposures. Chemosphere, 2021, 262, 128362.	4.2	15
1005	Assessing the utility of cardiorespiratory fitness, visceral fat, and liver fat in predicting changes in insulin sensitivity beyond simple changes in body weight after exercise training in adolescents. Applied Physiology, Nutrition and Metabolism, 2021, 46, 55-62.	0.9	3
1006	The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e300-e315.	1.8	17
1007	Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. Diabetes Care, 2021, 44, 489-498.	4.3	42
1008	Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Reports, 2021, 3, 100197.	2.6	41
1009	The Prevalence of Nonalcoholic Fatty Liver Disease and Its Risk Factors in Children and Young Adults with Type 1 Diabetes Mellitus. Journal of Pediatrics, 2021, 230, 32-37.e1.	0.9	4
1010	Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Annals of Medicine, 2021, 53, 1257-1265.	1.5	24
1011	Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut, 2021, 70, 2085-2095.	6.1	120
1012	Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clinical Nutrition, 2021, 40, 207-216.	2.3	28
1013	Combined <scp>exenatide</scp> and <scp>dapagliflozin</scp> has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: <scp>EXENDA</scp> , a 24â€week, prospective, randomized, placeboâ€controlled pilot trial. Diabetes, Obesity and Metabolism, 2021, 23, 1129-1139.	2.2	29
1014	Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-12.	0.8	16
1015	lcaritin ameliorates hepatic steatosis via promoting fatty acid β-oxidation and insulin sensitivity. Life Sciences, 2021, 268, 119000.	2.0	10
1016	Long-term inter-platform reproducibility, bias, and linearity of commercial PDFF MRI methods for fat quantification: a multi-center, multi-vendor phantom study. European Radiology, 2021, 31, 7566-7574.	2.3	9
1017	High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	14
1018	Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives. Current Obesity Reports, 2021, 10, 134-161.	3.5	40
1019	Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. Gene, 2021, 775, 145431.	1.0	13
1020	Atypical Hepatic Steatosis Patterns on MRI After Total Pancreatectomy With Islet Autotransplant. American Journal of Roentgenology, 2021, 217, 100-106.	1.0	3

#	Article	IF	CITATIONS
1021	Hepatic Steatosis in Patients With Single Ventricle and a Fontan Circulation. Journal of the American Heart Association, 2021, 10, e019942.	1.6	2
1022	The association between cardiorespiratory fitness, liver fat and insulin resistance in adults with or without type 2 diabetes: a cross-sectional analysis. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 40.	0.7	12
1023	Comparison of Multimaterial Decomposition Fat Fraction with DECT and Proton Density Fat Fraction with IDEAL IQ MRI for Quantification of Liver Steatosis in a Population Exposed to Chemotherapy. Dose-Response, 2021, 19, 155932582098493.	0.7	7
1024	In Vivo Magnetic Resonance Spectroscopy of Hyperpolarized [<scp>1â€¹³C</scp>]Pyruvate and Proton Density Fat Fraction in a Guinea Pig Model of Nonâ€Alcoholic Fatty Liver Disease Development After Lifeâ€Long Western Diet Consumption. Journal of Magnetic Resonance Imaging, 2021, 54, 1404-1414	1.9	3
1025	Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Molecular Metabolism, 2021, 53, 101262.	3.0	9
1026	Metabolomics of extracellular compounds and parasitic enzymes of Beauveria bassiana associated with biological control of whiteflies (Bemisia tabaci). Pesticide Biochemistry and Physiology, 2021, 176, 104877.	1.6	6
1027	Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184, 2537-2564.	13.5	757
1028	Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. Diagnostics, 2021, 11, 842.	1.3	16
1030	Hepatic Steatosis Has No Effect in Diagnosis Accuracy of <scp>Llâ€RADS</scp> v2018 Categorization of Hepatocellular Carcinoma in <scp>MR</scp> Imaging. Journal of Magnetic Resonance Imaging, 2021, , .	1.9	1
1031	Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3881-e3889.	1.8	11
1032	Low-carbohydrate diets lead to greater weight loss and better glucose homeostasis than exercise: a randomized clinical trial. Frontiers of Medicine, 2021, 15, 460-471.	1.5	11
1033	Determinants of hepatic insulin clearance $\hat{a} \in$ Results from a Mendelian Randomization study. Metabolism: Clinical and Experimental, 2021, 119, 154776.	1.5	2
1034	Impact of iron deposit on the accuracy of quantifying liver fat fraction using multiâ€material decomposition algorithm in dualâ€energy spectral computed tomography. Journal of Applied Clinical Medical Physics, 2021, 22, 236-242.	0.8	4
1035	Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 8004.	1.2	0
1036	A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells, 2021, 10, 1822.	1.8	24
1037	Diagnosis of Nonalcoholic Steatohepatitis. , 0, , .		0
1038	Hepatic Fat in Early Childhood Is Independently Associated With Estimated Insulin Resistance: The Healthy Start Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3140-3150.	1.8	10
1039	Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Seminars in Liver Disease, 2021, , .	1.8	2

	CHAHONT	LPORT	
#	Article	IF	CITATIONS
1040	A comparison of liver fat fraction measurement on MRI at 3T and 1.5T. PLoS ONE, 2021, 16, e0252928.	1.1	2
1041	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2021, 27, 363-401.	4.5	152
1042	Gender-specific liver aging and magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2021, 11, 2893-2904.	1.1	8
1043	Multisite multivendor validation of a quantitative MRI and CT compatible fat phantom. Medical Physics, 2021, 48, 4375-4386.	1.6	10
1044	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. International Journal of Molecular Sciences, 2021, 22, 7702.	1.8	18
1045	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med, 2021, 2, 814-835.e6.	2.2	12
1046	What's New in Hepatic Steatosis. Seminars in Ultrasound, CT and MRI, 2021, 42, 405-415.	0.7	7
1047	Imaging biomarkers of NAFLD, NASH, and fibrosis. Molecular Metabolism, 2021, 50, 101167.	3.0	83
1048	Reliability of ultrasound hepatorenal index and magnetic resonance imaging proton density fat fraction techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy as the reference standard. PLoS ONE, 2021, 16, e0255768.	1.1	6
1049	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Review of Molecular Diagnostics, 2021, 21, 1065-1078.	1.5	6
1050	Non-alcoholic fatty liver disease: time for changes. Mìžnarodnij EndokrinologìÄnij Žurnal, 2021, 17, 334-345.	0.1	3
1051	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clinical Therapeutics, 2021, 43, 1505-1522.	1.1	6
1052	Quantification of Liver Fat Content with CT and MRI: State of the Art. Radiology, 2021, 301, 250-262.	3.6	77
1053	Significance of liver fat loss in chronic liver disease: Usefulness of hepatic proton density fat fraction measurement by magnetic resonance imaging in evaluating malnutrition. Acta Hepatologica Japonica, 2021, 62, 525-537.	0.0	0
1054	Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. European Radiology, 2022, 32, 2070-2077.	2.3	13
1055	Hepatic Iron Quantification Using a <scp>Freeâ€Breathing 3D</scp> Radial Gradient Echo Technique and Validation With a <scp>2D</scp> Biopsyâ€Calibrated <scp>R₂</scp> [*] Relaxometry Method. Journal of Magnetic Resonance Imaging, 2022, 55, 1407-1416.	1.9	6
1056	The role of hepatic lipid composition in obesityâ€related metabolic disease. Liver International, 2021, 41, 2819-2835.	1.9	23
1057	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107978.	1.2	5

#	Article	IF	CITATIONS
1058	Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota. Cell Reports Medicine, 2021, 2, 100397.	3.3	35
1059	Associations of Nutrient Intake Changes During Childhood with Adolescent Hepatic Fat: The Exploring Perinatal Outcomes Among CHildrenAStudy. Journal of Pediatrics, 2021, 237, 50-58.e3.	0.9	3
1060	Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy. Annals of Hepatology, 2021, 25, 100358.	0.6	3
1061	Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. , 2021, , 115-137.		0
1062	Effect of a Low-Fat Vegan Diet on Body Weight, Insulin Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid Levels in Overweight Adults. JAMA Network Open, 2020, 3, e2025454.	2.8	85
1064	Magnetic Resonance Imaging in Pharmaceutical Safety Assessment. , 2006, , 385-393.		3
1065	Imaging Techniques for the Assessment of Ectopic Fat in Liver and Skeletal Muscle. , 2015, , 99-119.		2
1067	Obesity and the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2014, , 121-135.		2
1068	Uric Acid Metabolism and Uric Acid Stones. , 2010, , 185-193.		1
1069	Nonalcoholic Fatty Liver Disease in Children. , 2016, , 339-362.		1
1070	Clinical Epidemiology of NAFLD. , 2019, , 211-227.		3
1073	Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects. Digestive and Liver Disease, 2018, 50, 168-174.	0.4	7
1074	The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial. , 2021, 31, 611-619.		8
1075	Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. American Journal of Clinical Nutrition, 2021, 113, 391-400.	2.2	37
1076	The Severity of Histologic Liver Lesions Is Independent of Body Mass Index in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2013, 47, 280-286.	1.1	39
1077	Focal Fat Sparing of the Liver. Clinical Nuclear Medicine, 2014, 39, e359-e361.	0.7	11
1078	Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCl Insight, 2019, 4, .	2.3	110
1079	Science, serendipity, and the single degree. Journal of Clinical Investigation, 2018, 128, 4218-4223.	3.9	2

#	Article	IF	CITATIONS
1080	Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. Journal of Clinical Investigation, 2009, 119, 70-9.	3.9	322
1081	Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. PLoS ONE, 2012, 7, e50117.	1.1	191
1082	Measurement of Pancreatic Volume by Abdominal MRI: A Validation Study. PLoS ONE, 2013, 8, e55991.	1.1	35
1083	Clinical Implications of Non-Steatotic Hepatic Fat Fractions on Quantitative Diffusion-Weighted Imaging of the Liver. PLoS ONE, 2014, 9, e87926.	1.1	7
1084	Association of Liver Enzymes and Computed Tomography Markers of Liver Steatosis with Familial Longevity. PLoS ONE, 2014, 9, e91085.	1.1	8
1085	Temporal Relationship between Diet-Induced Steatosis and Onset of Insulin/Leptin Resistance in Male Wistar Rats. PLoS ONE, 2015, 10, e0117008.	1.1	19
1086	Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2015, 10, e0138889.	1.1	66
1087	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0160526.	1.1	26
1088	Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population. PLoS ONE, 2017, 12, e0175762.	1.1	9
1089	Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS ONE, 2018, 13, e0192663.	1.1	34
1090	Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. Journal of Clinical and Translational Hepatology, 2017, 5, 67-75.	0.7	18
1091	Comparison of sonographic hepatorenal ratio and the degree of hepatic steatosis in magnetic resonance imaging-proton density fat fraction. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ,-SzopiÅ,,ska, 2020, 20, 169-175.	0.7	10
1092	Risk Factor Prevalence and Their Relative Influence on Fatty Liver and Gallstone Disease: A Cross-Ethnic Study Comparing Two High-Risk Populations from Chile and Northeast Germany. Epidemiology - Open Journal, 2016, 1, 40-52.	0.4	1
1093	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Current Hypertension Reviews, 2021, 17, 94-111.	0.5	9
1095	Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications. Efficacy and Mechanism Evaluation, 2016, 3, 1-800.	0.9	5
1096	Current and future applications ofin vitromagnetic resonance spectroscopy in hepatobiliary disease. World Journal of Gastroenterology, 2006, 12, 4773.	1.4	22
1097	Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2006, 12, 5813.	1.4	100
1098	Liver fat content determined by magnetic resonance imaging and spectroscopy. World Journal of Gastroenterology, 2010, 16, 1560.	1.4	107

#	Article	IF	CITATIONS
1099	Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World Journal of Gastroenterology, 2012, 18, 1508.	1.4	84
1100	Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World Journal of Gastroenterology, 2014, 20, 9330-7.	1.4	328
1101	Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 15070.	1.4	19
1102	Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World Journal of Gastroenterology, 2014, 20, 17985-17992.	1.4	33
1103	Hepatic fat quantification magnetic resonance for monitoring treatment response in pediatric nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2015, 21, 9741.	1.4	8
1104	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism, 2020, 35, 243-259.	1.3	23
1105	MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quantitative Imaging in Medicine and Surgery, 2013, 3, 192-5.	1.1	28
1106	Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surgery and Nutrition, 2015, 4, 109-16.	0.7	96
1107	Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. Indian Journal of Radiology and Imaging, 2016, 26, 5-14.	0.3	15
1108	Prevention mechanism of 2,3,5,4'-tetrahydroxy-stilbene-2-o-l̂2-D-glucoside on lipid accumulation in steatosis hepatic L-02 cell. Pharmacognosy Magazine, 2017, 13, 245.	0.3	15
1109	Review of clinical studies of Polygonum multiflorum Thunb. and its isolated bioactive compounds. Pharmacognosy Research (discontinued), 2015, 7, 225.	0.3	85
1110	Nonalcoholic fatty liver disease and risk of diabetes and cardiovascular disease: What is important for primary care physicians?. Journal of Family Medicine and Primary Care, 2015, 4, 45.	0.3	40
1111	Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. Journal of Medical Ultrasound, 2019, 27, 19-25.	0.2	10
1112	Effect of Vitamin E and Alpha Lipoic Acid in Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Open-Label, Prospective Clinical Trial (VAIN Trial). Open Journal of Gastroenterology, 2014, 04, 199-207.	0.1	9
1113	Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population. World Journal of Hepatology, 2020, 12, 149-159.	0.8	24
1114	Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World Journal of Hepatology, 2013, 5, 621.	0.8	26
1115	Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 769.	0.8	49
1116	Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World Journal of Radiology, 2011, 3, 105.	0.5	51

#	Article	IF	CITATIONS
1117	Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut and Liver, 2013, 7, 323-328.	1.4	23
1118	Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clinical and Experimental Hepatology, 2020, 6, 289-294.	0.6	20
1119	GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress. BMB Reports, 2020, 53, 317-322.	1.1	13
1120	Non-alcoholic fatty liver disease (NAFLD) - A novel common aspect of the metabolic syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2006, 150, 101-104.	0.2	22
1121	Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Journal of Diabetes Research, 2021, 2021, 1-8.	1.0	14
1122	A Case of Hepatitis C-Related Decompensated Cirrhosis Observed by MRI Imaging Data During Treatment With Direct-Acting Antiviral Agents. Cureus, 2021, 13, e19001.	0.2	Ο
1123	Quality Control of Magnetic Resonance Elastography Using Percent Measurable Liver Volume Estimation. Journal of Magnetic Resonance Imaging, 2022, 55, 1890-1899.	1.9	3
1124	Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. , 2007, , 553-560.		Ο
1125	Evolving Functional and Advanced Image Analysis Techniques for Adrenal Lesion Characterization. , 2009, , 1-14.		0
1126	12 Niet-alcoholische steatohepatitis. , 2009, , 119-126.		0
1127	Ultrasound findings of fatty liver using advanced ultrasonoscope equipped with differential tissue harmonic imaging: re-evaluation of diagnostic criteria in comparison with CT findings. Choonpa Igaku, 2010, 37, 587-592.	0.0	0
1128	Metagenomic Applications and the Potential for Understanding Chronic Liver Disease. , 2011, , 277-295.		Ο
1129	A Preliminary Application of Magnetic Resonance Spectroscopy for Quantitatively Assessing Hepatic Fat and the Efficacy of Anti-obesity Therapy. Journal of Analytical Science and Technology, 2011, 2, 187-193.	1.0	0
1130	Effect of Zingiber officinale on fatty liver induced by oxytetracycline in albino rats. The Egyptian Journal of Hospital Medicine, 2012, 46, 26-42.	0.0	11
1131	The Pre-Diabetic, Insulin-Resistant State. , 2012, , 433-452.		0
1132	Uric Acid Nephrolithiasis: Basic and Clinical Aspects. , 2012, , 155-164.		0
1134	Definition – Klassifikation – Untersuchungsmethoden. , 2013, , 1-23.		0
1135	Les phénotypes d'obésité: mesure de la masse adipeuse chez l'homme. , 2013, , 249-260.		0

#	Article	IF	CITATIONS
1136	Hepatic Lipid Metabolism and Herbal Impacts on Non-Alcoholic Fatty Liver Disease. Journal of Food & Nutritional Disorders, 2013, 02, .	0.1	0
1137	Fatty Liver Disease among other Comorbidities Requiring Early Diagnosis in Pediatric Obesity. Obesity & Control Therapies: Open Access, 2013, 1, .	0.3	3
1139	Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2014, , 351-370.		0
1140	Obesity and the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2014, , 121-135.		0
1141	Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?. Clinical and Molecular Hepatology, 2014, 20, 151.	4.5	0
1142	Clinical Aspects of Nonalcoholic Fatty Liver Disease. Oxidative Stress and Disease, 2014, , 3-24.	0.3	0
1143	Role of adipokines in the pathogenesis of nonalcoholic fatty liver disease. The Journal of Clinical and Scientific Research, 2015, 4, 31.	0.1	1
1144	Current Approaches to the Diagnosis and Screening for Metabolic Disorders in Patients with Nonalcoholic Fatty Liver Disease. Mìžnarodnij EndokrinologìÄnij Žurnal, 2016, .	0.1	0
1145	EFFECT OF HIGH INTENSITY INTERVAL TRAINING VERSUS RESISTANCE TRAINING ON QUALITY OF LIFE AND FUNCTIONAL CAPACITY ON PATIENTS WITH FATTY LIVER DISEASES (PART I). Egyptian Journal of Occupational Medicine, 2016, 40, 61-70.	0.2	0
1146	HEPATITIS "Câ€, FREQUENCY OF HEPATIC STEATOSIS IN NON RESPONDER PATIENTS. The Professional Medical Journal, 2016, 23, 1068-1072.	0.0	0
1147	A Simple Model to Predict Moderate to Severe Steatosis in Obese Liver Donors. Journal of Obesity and Chronic Diseases, 2017, 01, .	0.4	0
1148	Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine, 2018, 70, 570-576.	0.0	0
1149	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease. , 2018, , 391-405.e3.		1
1150	استú©Ø′اù•اù"ù†Ø′اØ∙ااù"ù^اù,ùŠ ù"ù"ú©Ø [~] Ø⁻ ù"Ø [~] ù"سù… اù"ù"ùŠù…ù^ù† (Melissa	ofoicoinalis	L.)¢Ø¶Ø⁻ Ø <mark>S</mark> I
1151	The protective effect of ginger extract on induced fatty liver in Albino rats: Histological and biochemical study. Benha Veterinary Medical Journal, 2019, 36, 32-42.	0.0	1
1152	Ectopic Fat and Insulin Resistance in Youth. Contemporary Endocrinology, 2020, , 155-167.	0.3	0
1153	The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. Electronic Journal of General Medicine, 2019, 16, em165.	0.3	0
1154	Non-Invasive Analysis of Human Liver Metabolism by Magnetic Resonance Spectroscopy. Metabolites, 2021, 11, 751.	1.3	5

#	Article	IF	CITATIONS
1155	Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World Journal of Clinical Cases, 2021, 9, 9333-9349.	0.3	5
1156	Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. Current Drug Metabolism, 2020, 21, 746-750.	0.7	3
1157	Applications of Fat Mapping. Advances in Magnetic Resonance Technology and Applications, 2020, 1, 735-777.	0.0	1
1158	Cancer de la cavité orale chez trois frères germains en Mauritanie. Pan African Medical Journal, 2020, 37, 270.	0.3	3
1159	Exercise and Type 2 Diabetes Mellitus: Changes in Tissue-specific Fat Distribution and Cardiac Function. Radiology, 2013, 269, 434-442.	3.6	24
1160	Renal Lipids and Oxygenation in Diabetic Mice: Noninvasive Quantification with MR Imaging. Radiology, 0, , 122860.	3.6	0
1162	Pediatric obesity phenotyping by magnetic resonance methods. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 595-601.	1.3	19
1164	Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009, 13, 9-19.	0.3	345
1165	Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antiviral Therapy, 2008, 13, 423-8.	0.6	8
1166	Increasing Physical Activity Decreases Hepatic Fat and Metabolic Risk Factors. Journal of Exercise Physiology Online, 2012, 15, 40-54.	0.0	2
1167	Fatty liver disease in an autopsy series of children and adolescents. Hippokratia, 2012, 16, 61-5.	0.3	12
1168	Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Annals of Gastroenterology, 2012, 25, 45-51.	0.4	53
1170	Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterology and Hepatology, 2006, 2, 282-291.	0.2	11
1171	Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease. Hippokratia, 2018, 22, 10-16.	0.3	4
1172	Investigating the impact of eight weeks of aerobic and resistance training on blood lipid profile in elderly with non-alcoholic fatty liver disease: a randomized clinical trial. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 190-196.	0.6	3
1174	HCMV-encoded IE2 promotes NAFLD progression by up-regulation of SREBP1c expression in UL122 genetically modified mice. International Journal of Clinical and Experimental Pathology, 2018, 11, 4213-4220.	0.5	2
1175	Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, 2020, 31, 588-595.	0.4	0
1176	Hepatic Steatosis: CT-Based Prevalence in Adults in China and the United States and Associations With Age, Sex, and Body Mass Index. American Journal of Roentgenology, 2022, 218, 846-857.	1.0	4

#	Article	IF	CITATIONS
1177	Shear Wave Elastography Reveals a High Prevalence of NAFLD-related Fibrosis Even in Type 1 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2021, , .	0.6	3
1178	Role of Advanced MRI Techniques in the Quantitative Assessment of Liver Fat—A Multimodality-Based Comparative Study of Diagnostic Performance in a Tertiary Care Institute. Journal of Gastrointestinal and Abdominal Radiology, 0, , .	0.2	0
1179	Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy. Turkish Journal of Gastroenterology, 2020, 31, 588-595.	0.4	2
1180	Shortâ€Term Variability of Proton Density Fat Fraction in Pancreas and Liver Assessed by Multiecho Chemicalâ€Shift Encodingâ€Based <scp>MRI</scp> at 3ÂT. Journal of Magnetic Resonance Imaging, 2022, 56, 1018-1026.	1.9	8
1182	Vibration ontrolled transient elastography for noninvasive evaluation of liver steatosis. Medical Physics, 2022, , .	1.6	2
1183	Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. Frontiers in Endocrinology, 2022, 13, 830012.	1.5	3
1184	Breastfeeding may benefit cardiometabolic health of children exposed to increased gestational glycemia in utero. European Journal of Nutrition, 2022, 61, 2383-2395.	1.8	6
1185	Coronary Endothelial Dysfunction in People Living With HIV Is Related to Body Fat Distribution. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 201-207.	0.9	5
1186	Intrahepatic lipid content is independently associated with soluble E-selectin levels: The Maastricht study. Digestive and Liver Disease, 2022, 54, 1038-1043.	0.4	3
1187	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines, 2022, 10, 83.	1.4	71
1188	Evaluation of a Whole-Liver Dixon-Based MRI Approach for Quantification of Liver Fat in Patients with Type 2 Diabetes Treated with Two Isocaloric Different Diets. Diagnostics, 2022, 12, 514.	1.3	2
1189	Fructose Intake From Fruit Juice and Sugar-Sweetened Beverages Is Associated With Higher Intrahepatic Lipid Content: The Maastricht Study. Diabetes Care, 2022, 45, 1116-1123.	4.3	11
1190	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. International Journal of Molecular Sciences, 2022, 23, 2636.	1.8	11
1191	Clinical Intervention to Reduce Dietary Sugar Does Not Affect Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial. Journal of Nutrition, 2022, 152, 1655-1665.	1.3	8
1192	Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocrine Disorders, 2022, 22, 63.	0.9	199
1193	4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 21.	1.6	14
1194	The role of microbiota in nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2022, 52, e13768.	1.7	22
1195	Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial. Diabetes Research and Clinical Practice, 2022, 186, 109781.	1.1	15

#	Article	IF	CITATIONS
1196	Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. JCI Insight, 2022, 7, .	2.3	6
1197	Obesity-Related Metabolic Dysfunction in Dairy Cows and Horses: Comparison to Human Metabolic Syndrome. Life, 2021, 11, 1406.	1.1	11
1209	Noninvasive Assessment of Liver Fibrosis by Magnetic Resonance Elastography in Patients with Rheumatic Disease on Long-Term Methotrexate Treatment. Indian Journal of Rheumatology, 2023, 18, 54.	0.2	2
1210	Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. Obesity, 2022, 30, 1231-1238.	1.5	11
1211	A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients. Frontiers in Oncology, 2022, 12, 873524.	1.3	0
1212	Health burden in type 2 diabetes and prediabetes in The Maastricht Study. Scientific Reports, 2022, 12, 7337.	1.6	2
1213	Biosynthesis and characterization of extracellular metabolites-based nanoparticles to control the whitefly. Archives of Microbiology, 2022, 204, 311.	1.0	4
1214	Insulin Resistance, Hepatic Lipid and Adipose Tissue Distribution in HIV-Infected Men. Antiviral Therapy, 2008, 13, 423-428.	0.6	12
1215	Diffuse Liver Disease. , 2015, , 1629-1675.		0
1217	Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with ¹ H-MR Spectroscopy. Antiviral Therapy, 2007, 12, 195-204.	0.6	19
1218	Characterization of diet based nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes Histology and Histopathology, 2022, , 18462.	0.5	0
1219	Contribution of a genetic risk score to ethnic differences in fatty liver disease. Liver International, 2022, 42, 2227-2236.	1.9	16
1220	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones, 2022, 21, 349-368.	0.9	12
1222	The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food. Magnetic Resonance in Medical Sciences, 2023, 22, 263-271.	1.1	2
1223	<scp>MRI</scp> characterization of skeletal muscle size and fatty infiltration in longâ€ŧerm trained and untrained individuals. Physiological Reports, 2022, 10, .	0.7	1
1224	Steatosis Grading Comparison Between Qualitative Ultrasonography and Magnetic Resonance Spectroscopy in Patients With Nonalcoholic Fatty Liver Disease. Journal of Diagnostic Medical Sonography, 2023, 39, 33-41.	0.1	0
1225	The Potential of the Mediterranean Diet to Improve Mitochondrial Function in Experimental Models of Obesity and Metabolic Syndrome. Nutrients, 2022, 14, 3112.	1.7	23
1226	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers, 2022, 14, 4051.	1.7	11

	CITATION RI	EPORT	
#	Article	IF	CITATIONS
1227	Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of <scp>NASH</scp> even in lean individuals. Liver International, 2022, 42, 2418-2427.	1.9	28
1228	Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunctionâ€ [®] Associated Fatty Liver Disease (MAFLD). Diabetes, 2022, 71, 2402-2411.	0.3	3
1230	The spectrum of magnetic resonance imaging proton density fat fraction (MRI-PDFF), magnetic resonance spectroscopy (MRS), and two different histopathologic methods (artificial intelligence vs.) Tj ETQq0 C) 0 ₁₉ BT /C	Dverlock 10 T
1231	5251-5262. Fluid Mechanics Approach to Perfusion Quantification: Vasculature Computational Fluid Dynamics Simulation, Quantitative Transport Mapping (QTM) Analysis of Dynamics Contrast Enhanced MRI, and Application in Nonalcoholic Fatty Liver Disease Classification. IEEE Transactions on Biomedical Engineering, 2023, 70, 980-990.	2.5	2
1232	Clinical significance of hepatic fat loss in chronic liver disease: a study using MRI proton density fat fractionation. European Journal of Clinical Nutrition, 0, , .	1.3	0
1233	Lactation alters the relationship between liver lipid synthesis and hepatic fat stores in the postpartum period. Journal of Lipid Research, 2022, 63, 100288.	2.0	2
1234	Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study. Diabetologia, 2023, 66, 213-222.	2.9	7
1235	The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Review of Clinical Pharmacology, 2022, 15, 1199-1208.	1.3	11
1236	Association between high-sensitivity-CRP and liver elastography and cardiac ischemic diseases in patients with fatty liver. Journal of Family Medicine and Primary Care, 2022, 11, 5495.	0.3	2
1237	Obesity risk is associated with brain glucose uptake and insulin resistance. European Journal of Endocrinology, 2022, 187, 917-928.	1.9	5
1238	Timing of physical activity in relation to liver fat content and insulin resistance. Diabetologia, 2023, 66, 461-471.	2.9	20
1239	Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multiâ€ethnic population: Results from the Dallas Heart Study. Diabetes, Obesity and Metabolism, 2023, 25, 586-595.	2.2	0
1240	Associations between plasma sulfur amino acids and specific fat depots in two independent cohorts: CODAM and The Maastricht Study. European Journal of Nutrition, 0, , .	1.8	3
1241	NONINVASIVE DIAGNOSTICS OF NON-ALCOHOLIC STEATOHEPATITIS. Problemy Zdorovʹâ I èkologii, 2011, , 95-102.	0.0	0
1242	Cutoff Values for Diagnosing Hepatic Steatosis Using Contemporary MRI-Proton Density Fat Fraction Measuring Methods. Korean Journal of Radiology, 2022, 23, 1260.	1.5	4
1243	Lifestyle and Nonalcoholic Steatohepatitis. Advances in Clinical Medicine, 2022, 12, 10609-10616.	0.0	0
1244	Non-Invasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. European Medical Journal Hepatology, 0, , 80-85.	1.0	0
1245	Noninvasive Imaging Modalities in Nonalcoholic Fatty Liver Disease: Where Do We Stand?. European Medical Journal (Chelmsford, England), 0, , 57-62.	3.0	2

#	Article	IF	CITATIONS
1246	Magnetic Resonance Imaging in Pharmaceutical Safety Assessment. , 2022, , 1-19.		1
1247	Impact of Preoperative Protein Sparing Modified Fast Diet on Bariatric Surgery. Obesity Surgery, 0, , .	1.1	0
1248	Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction: Secondary Analysis of an RCT. Nutrients, 2022, 14, 5061.	1.7	1
1249	An Adapted Deep Convolutional Neural Network for Automatic Measurement of Pancreatic Fat and Pancreatic Volume in Clinical Multi-Protocol Magnetic Resonance Images: A Retrospective Study with Multi-Ethnic External Validation. Biomedicines, 2022, 10, 2991.	1.4	1
1250	Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP Reports, 2023, 5, 100663.	2.6	3
1251	Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
1252	Quantitative MRI of diffuse liver diseases: techniques and tissue-mimicking phantoms. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2023, 36, 529-551.	1.1	2
1253	Effect of unsaturated fat and protein intake on liver fat in people at risk of unhealthy aging: 1-year results of a randomized controlled trial. American Journal of Clinical Nutrition, 2023, 117, 785-793.	2.2	1
1254	Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. Nephron, 2023, 147, 317-328.	0.9	3
1255	A Comparative Study of Ultrasound Attenuation Imaging, Controlled Attenuation Parameters, and Magnetic Resonance Spectroscopy for the Detection of Hepatic Steatosis. Journal of Ultrasound in Medicine, 2023, 42, 1481-1489.	0.8	3
1256	Updates on Quantitative MRI of Diffuse Liver Disease: A Narrative Review. BioMed Research International, 2022, 2022, 1-15.	0.9	2
1257	Exploring the relationship between pancreatic fat and insulin secretion in overweight or obese women without type 2 diabetes mellitus: A preliminary investigation of the TOFI_Asia cohort. PLoS ONE, 2022, 17, e0279085.	1.1	1
1258	Obesity in relation to cardiorenal function. , 2023, , 243-264.		0
1259	Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats. Frontiers in Veterinary Science, 0, 10, .	0.9	1
1260	Overall, abdominal, and visceral obesity in men and women: an introduction. , 2023, , 3-18.		0
1261	Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2023, 24, 2844.	1.8	20
1262	The Link between NAFLD and Metabolic Syndrome. Diagnostics, 2023, 13, 614.	1.3	10
1263	Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn's Disease. Crohn's & Colitis 360, 2023, 5, .	0.5	0

#	Article	IF	CITATIONS
1264	Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease. Atherosclerosis, 2023, 372, 10-18.	0.4	3
1265	Monte Carlo modeling of hepatic steatosis based on stereology and spatial distribution of fat droplets. Computer Methods and Programs in Biomedicine, 2023, 233, 107494.	2.6	0
1266	Mediterranean diet and mitochondria: New findings. Experimental Gerontology, 2023, 176, 112165.	1.2	5
1267	Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissueâ€specific insulin sensitivity in patients with earlyâ€stage type 2 diabetes with nonâ€slcoholic fatty liver disease: A prospective randomized study. Diabetes, Obesity and Metabolism, 2023, 25, 1576-1588.	2.2	9
1268	Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS ONE, 2023, 18, e0281508.	1.1	1
1269	A Healthful Plant-Based Eating Pattern Is Longitudinally Associated with Higher Insulin Sensitivity in Australian Adults. Journal of Nutrition, 2023, 153, 1544-1554.	1.3	1
1270	Correlation between Liver Fat Content and Iron Content in Patients with Non Alcoholic Fatty Liver Disease. Advances in Clinical Medicine, 2023, 13, 4711-4718.	0.0	0
1271	Accuracy of Evaluation of Fatty Liver with Third-Generation Unenhanced Dual-Energy CT and MRI: Prospective Comparison with MR Spectroscopy. Journal of Gastrointestinal and Abdominal Radiology, 0, , .	0.2	0
1272	The effect of hepatic steatosis on liver volume determined by proton density fat fraction and deep learning–measured liver volume. European Radiology, 0, , .	2.3	0
1273	Fatty Liver Disease. , 2024, , 330-401.		1
1274	Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. JHEP Reports, 2023, 5, 100753.	2.6	5
1275	ldentifying disease progression in chronic kidney disease using proton magnetic resonance spectroscopy. Progress in Nuclear Magnetic Resonance Spectroscopy, 2023, 134-135, 52-64.	3.9	1
1276	Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes. Diabetes, 2023, 72, 898-907.	0.3	2
1277	Recent progresses on pathophysiology, diagnosis, therapeutic modalities, and management of Non-alcoholic fatty liver disorder. Current Drug Therapy, 2023, 18, .	0.2	0
1278	Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease. Acta Diabetologica, 0, , .	1.2	0
1284	Comorbid Conditions of Pediatric Obesity. , 2023, , 153-198.		0
1311	Metabolic-Associated Fatty Liver Disease: Opportunistic Screening at CT Colonography. , 2023, , 277-290.		0